

CURRICULUM VITAE

Name: Michael Piers Osborne MB, MSurg, FRCS, FACS

Address: 330 East 39th Street, Suite 27H
New York, NY 10016
Tel: (212) 844-8770
Fax: (212) 844-8954
E-mail: michaelosbornemd@aol.com
Website: michaelosbornemd.us

Date of Birth: January 6, 1946

Place of Birth: Sutton, Surrey, England

Nationality: United States and United Kingdom

Education: University of London,
Charing Cross Hospital Medical School, 1965-1970

Qualifications: LRCP Licentiate, Royal College of Physicians of London 1970
MRCS Member, Royal College of Surgeons of England 1970
MB Bachelor of Medicine, University of London 1970
BS Bachelor of Surgery, University of London 1970
FRCS Fellow, Royal College of Surgeons of England 1975
MS Master of Surgery, University of London 1980
FACS Fellow, American College of Surgeons 1984

Postdoctoral Training:

House Physician, West London Hospital (Charing Cross Group of Hospitals)	Internal Medicine July 1, 1970 - December 31, 1970
House Surgeon to the Professorial Department of Surgery, Fulham Hospital (Charing Cross Group of Hospitals)	General Surgery January 1, 1971 - June 30, 1971
Institute of Basic Medical Sciences Royal College of Surgeons of England	Surgical Science October 1, 1971 - February 29, 1972
Senior House Officer, West Middlesex Hospital, Isleworth	Accident and Emergency Surgery March 4, 1972 - September 5, 1972
Senior House Officer, St. James Hospital, London	General Surgery and Urology October 1, 1972 - March 31, 1973
Resident Surgical Officer, Brompton Hospital, London	Cardiothoracic Surgery April 1, 1973 - September 30, 1973

Registrar, West Herts Hospital
Hertfordshire

General Surgery, Orthopedics
and Trauma
October 1, 1973 - January 11, 1976

Registrar,
Charing Cross Hospital, London

General Surgery, Surgical Oncology
January 12, 1976 - September 30, 1978

Lecturer in Surgery and Wellcome Trust Fellow
Charing Cross Hospital Medical School
University of London

Breast Cancer Research
January 24, 1977 - January 23, 1978

Honorary Lecturer
Senior Registrar in General Surgery,
The Royal Marsden Hospital and
Institute of Cancer Research, London

Surgical Oncology, Breast Cancer Research
November 1, 1978 - June 30, 1980

Fellow in Surgical Oncology, Dept. of Surgery
Memorial Sloan-Kettering Cancer Center, NY

Surgical Oncology
July 1, 1980-June 30, 1981

Previous Appointments:

Assistant Professor of Surgery,
Cornell University Medical College, NY

July 1, 1981 - June 30, 1984

Assistant Attending Surgeon
Memorial Hospital, NY

July 1, 1981 - March 21, 1990

Adjunct Faculty Member,
The Rockefeller University, NY

October 1, 1981 - September 30, 1989

Visiting Associate Physician,
The Rockefeller University Hospital, NY

August 1, 1983 – June 30, 2007t

Assistant Member,
Memorial Sloan-Kettering Cancer Center, NY

July 1, 1984 - March 21, 1990

Associate Professor of Surgery,
Cornell University Medical College, NY

July 1, 1984 - November 30, 1991

Head, Breast Cancer Research Laboratory
Memorial Sloan-Kettering Cancer Center, NY

July 1, 1986 - August 31, 1991

Associate Member,
Memorial Sloan-Kettering Cancer Center, NY

March 22, 1990 - August 31, 1991

Associate Attending Surgeon,
Memorial Hospital, NY

March 22, 1990 - August 31, 1991

Director and Chief Executive Officer,
Strang Cancer Prevention Center, NY

September 1, 1991 - July 1, 1995

President and Chief Executive Officer
Strang Cancer Prevention Center, NY

July 1, 1995 – June 30 2007

Chief, Breast Service, Department of Surgery
The New York Presbyterian Hospital-Cornell Medical Center, NY

September 1, 1991 – June 30 2007

Professor of Surgery
Cornell University Medical College, NY

December 1, 1991 – June 30 2007

Attending Surgeon

September 1, 1991 – June 30 2007

The New York Presbyterian Hospital-Cornell Medical Center, NY

Adjunct Professor
The Rockefeller University, NY

July 1, 2003 – June 30 2007

Director, Breast Programs
Continuum Cancer Centers of New York

July 1 2007 – March 31, 2011

Current Appointments:

Attending Surgeon, Comprehensive Breast Center
Beth Israel Medical Center

July 1 2007 – present

President, Strang Cancer Prevention Institute

September 18 2009 – present

Director, Strang Cancer Prevention Programs
Continuum Cancer Centers of New York

April 1 2011 – present

Licensed Physician #: 145757

1981 – New York

Board Certification (equivalent):

1982 Certification of Higher Surgical
Training in General Surgery,
Royal College of Surgeons of England

Scientific and Medical Societies:

American Society of Breast Surgeons
American Surgical Association
Fellow, Royal Society of Medicine
Memorial Hospital Alumni Society
New York Cancer Society
New York Clinical Society
New York Metropolitan Breast Cancer Group
New York Surgical Society
Physician's Scientific Society
Society of Surgical Oncology
The Halsted Society
Worshipful Society of Apothecaries

Honors and Awards:**Undergraduate:**

The Golding Medal (The Governor's Clinical Gold Medal)
 Llewelyn Scholarship
 Norman C. Lake Prize in Surgery
 William Travers Prize in Obstetrics and Gynecology
 Thomas Henry Green Prize in Clinical Medicine
 Prize in Orthopedics
 Prize in Gynecology
 Prize in Radiology
 David Winsor Essay Prize
 Prize in Second Clinical Year Surgery
 Certificate of Merit in Psychiatry
 Certificate of Merit in Third Clinical Year Medicine
 Certificate of Merit in Second Clinical Year Medicine
 Certificate of Merit in First Clinical Year Surgery
 Certificate of Merit in Anatomy Dissection

Postgraduate:

Wellcome Trust Surgical Fellowship (1977 - 1978)
 Simpson-Smith Surgical Travel Scholarship (1977)
 Raven Prize, British Association of Surgical Oncologists (1978)
 Gosse Scholarship, Charing Cross Hospital Medical School (1980)
 Distinguished Scientist, National University of Cordoba, Republic of Argentina (1990)
 Albert Segaloff Memorial Lecturer, Alton Ochsner Medical Foundation (1991)
 Cyril S. Avranitis Lecturer, Monmouth Medical Center (1994)
 Ellen Dryer Memorial Lecture, Sass Foundation New York (2001)

Other Activities:

American Cancer Society Institutional Grants Review Committee,
 Memorial Sloan-Kettering Cancer Center 1986-1989
 Education Committee, Society of Surgical Oncology 1988-1990
 Vice-President, New York Metropolitan Breast Cancer Group 1989-1991
 Chairman, Research Committee, New York Metropolitan Breast Cancer Group
 1991-1995
 Breast Tumor Board, New York Hospital-Cornell Medical Center 1991-present
 Cancer Care Committee, New York Hospital-Cornell Medical Center 1991-2007
 Member, Board of Trustees, Strang Cancer Prevention Center 1991-present
 Member, Executive Committee, Strang Cancer Prevention Center 1991-present
 Scientific Advisory Board, American-Italian Foundation 1991-present
 National Institutes of Health, National Cancer Institute, Workshop on Bone
 Marrow Micrometastases 1992
 Cancer & Leukemia Group B, Breast Surgeon Committee 1992
 Board of Trustees, National Consortium of Breast Centers 1992-1995
 Executive Board, Society for the Study of Breast Disease 1992-1995
 Medical Advisory Board, National Alliance of Breast Cancer Organizations 1992-2000
 Chairman, Program Committee, 20th Annual Symposium of the New York Metropolitan
 Breast Cancer Group 1993
 Vice-President, New York Metropolitan Breast Cancer Group 1993-1995
 Cornell University Medical College Faculty Practice Plan/Clinical Affairs Task
 Force on Highly Specialized Services 1995
 President, New York Metropolitan Breast Cancer Group 1995-1997
 Board of Advisors, New York Menopause Center 1995-present
 Secretary General, International Society of Cancer Chemoprevention 1996-2002
 Breast Cancer Advisory Board, Schering-Plough, 1996
 The New York Hospital-Presbyterian Network, CEO Committee 1997-2000
 Editorial Board, Breast Cancer Online 1998-present
 Editorial Board, Seminars in Breast Disease 1998-present

Member of the Board, New York and Presbyterian Healthcare Network 1998-2000
Breast Cancer Advisory Board, AstraZeneca, 1999
Treasurer, International Society of Cancer Chemoprevention 2002-2007
Committee Member, American Association for Cancer Research
– Career Development Award 2002.
Local Arrangements Committee. Society of Surgical Oncology
57th Annual Cancer Symposium, New York City 2004.
Audit Committee, Halsted Society 2003-2005
President, New York Clinical Society 2005-2006
Member of the Board, the American Friends of Cancer Relief Macmillan Fund
2006-present
President-Elect, The New York Surgical Society 2013

Ad Hoc Reviewer

New England Journal of Medicine
Lancet
Lancet Oncology
Annals of Surgery
Journal of Clinical Oncology
Annals of Surgical Oncology
Nature Reviews Drug Discovery
Cancer Research
British Journal of Surgery
Journal of the National Cancer Institute
International Journal of Cancer
American Journal of Pathology
American Journal of Surgery
Breast Cancer Review

Editorial Board

Breast Cancer On Line – www.bco.org

Guest Editor

Osborne MP
Breast cancer prevention
Seminars in Breast Disease 2003 volume 6

Books:

Cancer Prevention From the Laboratory to the Clinic: Implications of Genetic, Molecular and Preventive Research
Eds: H.L. Bradlow, **M.P. Osborne**, U. Veronesi
Annals of the New York Academy of Sciences Vol. 768. 1995

Strang Cookbook for Cancer Prevention
Authors: L. Pensiero, S. Oliveria, **M. Osborne**. Dutton. 1998

Cancer Prevention: Novel Nutrient and Pharmaceutical Developments
Eds: H.L. Bradlow, J. Fishman, **M.P. Osborne**
Annals of the New York Academy of Sciences Vol. 889. 1999

Cancer Prevention: Molecular Mechanisms to Clinical Applications.
Eds: **M.P. Osborne**
Annals of New York Academy of Sciences Vol. 952. 2001

Strang Cookbook for Cancer Prevention
Authors: L. Pensiero, S. Oliveria, **M. Osborne**. McGraw Hill. 2004

Public Recognition:

1989	Good Housekeeping	The 184 Best Breast Cancer Doctors in America
1991	New York Magazine	Best Doctors
1992	Good Housekeeping	Best Cancer Specialists in the US
1992-1993	Woodward/White	Best Doctors in America
1993-present	Marquis	Who's Who in Science & Engineering
1994-present	Marquis	Who's Who in the World
1995	Town & Country	Best Medical Specialists in North America
1996-present	Marquis	Who's Who Worldwide
1996	American Health	Best Doctors in America
1996	New York Magazine	Best Doctors
1996	International Who's Who of Contemporary Achievement	
1996	5000 Personalities of the World	
1997	Castle Connolly	How to Find the Best Doctors: New York Metro Area
1998	Castle Connolly	How to Find the Best Doctors: New York Metro Area
1998	New York Magazine	Best Doctors
1999	Castle Connolly	How to Find the Best Doctors: New York Metro Area
1999	Good Housekeeping	318 Top Cancer Doctors for Women
2000	Castle Connolly	How to Find the Best Doctors: New York Metro Area
2000	Manhattan Magazine	5 th Annual Breast Cancer Awareness Award
2000	New York Magazine	Best Doctors
2001	New York Magazine	Best Doctors
2001	Castle Connolly	Top Doctors: New York Metro Area
2001-2002	Best Doctors	Best Doctors in America
2002	New York Magazine	Best Doctors
2002	Castle Connolly	America's Top Doctors
2003	Castle Connolly	Top Doctors: New York Metro Area
2003	New York Magazine	Best Doctors
2003	Castle Connolly	America's Top Doctors
2003-2004	Best Doctors	Best Doctors in America
2004	New York Magazine	Best Doctors
2004	Smith Barney Citigroup	Extraordinary Achievement Award "Women's Health Issues in conjunction with the Susan G. Komen Foundation 'Race for the Cure'
2004	Castle Connolly	America's Top Doctors
2004	Castle Connolly	Top Doctors: New York Metro Area
2005-2006	Best Doctors	Best doctors in America
2005	Castle Connolly	Top Doctors: New York Metro Area
2005	Castle Connolly	America's Top Doctors for Cancer
2005	Castle Connolly	America's Top Doctors
2005	New York Magazine	Best Doctors
2006	New York Magazine	Best Doctors
2006-2007	Best Doctors	Best Doctors in America
2006	Castle Connolly	America's Top Doctors
2006	Castle Connolly	Top Doctors: New York Metro Area
2006	Castle Connolly	America's Top Doctors for Cancer
2007	New York Magazine	Best Doctors
2007	Castle Connolly	America's Top Doctors
2007	Consumer's Research Council	Guide to America's Top Oncologists
2007-2008	Best Doctors	Best Doctors in America
2008	New York Super Doctors	New York Times Supplement
2008	New York Magazine	Best Doctors
2008	Castle Connolly	America's Top Doctors for Cancer
2009	New York Super Doctors	New York Times supplement
2009	New York Magazine	Best Doctors
2009-2012	Best Doctors	Best Doctors in America
2010-2012	Castle Connolly	Top Doctors in America
2010-2012	Castle Connolly	Top Cancer Doctors in America
2010-2012	New York Magazine	Best Doctors
2010-2014	New York Super Doctors	New York Times Supplement

Bibliography

Peer Reviewed Publications

1. **Osborne MP**, Paneth M, Hinson KFW.
Starch granules in the pericardium as a cause of post-cardiotomy syndrome
Thorax 1974;29:199-203
2. **Osborne MP**.
Penile Parkinsonism
Postgraduate Medical Journal 1974;50:523-524
3. Honey M, Lincoln JCR, **Osborne MP**, DeBono D.
Coarctation of the aorta with right aortic arch
British Heart Journal 1975;37:937-945
4. **Osborne MP**, Hamilton G, Shalley M.
Axial volvulus of Meckel's diverticulum
Postgraduate Medical Journal 1978;54:692-693
5. Bion J, Coleman JC, **Osborne MP**.
An unusual postoperative pneumonia
Journal of the Royal Society of Medicine 1978;71:523-526
6. Ryman BE, Jewkes RF, Jeyasingh K, **Osborne MP**, Patel HM, Richardson VJ, Tyrell DA.
Potential applications of liposomes to therapy
Annals of the New York Academy of Sciences 1978;308:281-307
7. **Osborne MP**, Murray-Lyon IM, Reynolds K.
Dacron bypass grafting in the relief of obstructive jaundice
Lancet 1979;1:1323-1325
8. **Osborne MP**, Richardson VJ, Jeyasingh K, Ryman BE.
Radionuclide labeled liposomes - a new lymph node imaging agent
International Journal of Nuclear Medicine and Biology 1979;6:75-83
9. **Osborne MP**, Jeyasingh K, Jewkes RF, Burns JI.
The preoperative detection of internal mammary lymph node metastases in breast cancer
British Journal of Surgery 1979;66:813-818
10. **Osborne MP**.
Lymph node scanning for breast cancer
Transactions of the Medical Society of London 1979;95:43-45
11. Greening WP, Sarker SK, **Osborne MP**.
Hemiagenesis of the thyroid gland
British Journal of Surgery 1980;67:446-448

12. Sarker SK, **Osborne MP**, Harmer CL, Greening WP.
Thyroid cancer - a study of 220 cases
Indian Journal of Cancer 1980;17:11-18
13. **Osborne MP**.
The detection of lymphatic metastases in breast cancer
Master of Surgery Thesis, University of London, 1980
14. **Osborne MP**, Richardson VJ, Jeyasingh K, Ryman BE.
Potential applications of radionuclide-labeled liposomes in the detection of the lymphatic spread of cancer
International Journal of Nuclear Medicine, Biology and Physics 1982;9:47-51
15. **Osborne MP**, Griffiths JD, Shaw HJ.
Colon-transposition in the management of upper gastrointestinal cancer
Cancer 1982;50:257-264
16. Freeman JL, Brondbo K, **Osborne MP**, Novek AM, Shaw HJ, Rubin A, Chapnick JS.
Greater momentum used for carotid cover after pharyngolaryngoesophagectomy and gastric "pull-up" or colonic "swing"
Archives of Otolaryngology 1982;108:685-687
17. **Osborne MP**, Payne JH, Richardson VJ, McCreedy VR, Ryman BE.
The preoperative detection of axillary lymph node metastases in breast cancer by isotope imaging
British Journal of Surgery 1983;70:141-144
18. **Osborne MP**.
Pedal microlymphangiography in the experimental animal
Lymphology 1983;16:31-34
19. **Osborne MP**, Rosen PP, Lesser ML, Schwartz MK, Menendez-Botet CJ, Fishman J, Kinne DW, Beattie EJ Jr.
The relationship between family history, exposure to exogenous hormones and estrogen receptor protein in breast cancer
Cancer 1983;51:2134-2138
20. Fracchia AA, Cody HS, Eisenberg BL, **Osborne MP**, Owens JC, Weingrad DN, Caron AS, Urmacher C, Bretsky S.
Stage II carcinoma of the breast: The importance of adequate local therapy
Breast 1983;9:23-29
21. **Osborne MP**, Ormiston N, Harmer CL, McKinna JA, Baker J, Greening WP.
Breast conservation in the treatment of early breast cancer: A 20-year follow-up
Cancer 1984;53:349-355
22. Petrek JA, Dukoff R, Crowe J, **Osborne MP**, Kinne DW.
Pregnancy-associated breast cancer
Surgical Forum 1986;38:478-480

23. Axelrod DM, Bockman RS, Wong GY, **Osborne MP**, Kinne DW, Brennan MF.
Distinguishing features of primary hyperparathyroidism in patients with breast cancer.
Cancer 1987;60:160-1624
24. McCormick B, Kinne D, Petrek J, **Osborne MP**, Cox L, Shank B, Hellman S, Yahalom J, Rosen PP.
Limited resection for breast cancer: A study of inked specimen margins before radiotherapy
International Journal of Radiation Oncology, Biology, Physics 1987;13:1667-1671
25. Cote RJ, Rosen PP, Hakes TB, Sedira M, Bazinet M, Kinne DW, Old LJ, **Osborne MP**.
Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease
American Journal of Surgical Pathology 1988;12:333-340
26. Axelrod DM, Menendez-Botet CJ, Kinne DW, **Osborne MP**.
Levels of estrogen and progesterone receptor proteins in patients with breast cancer during various phases of the menstrual cycle
Cancer Investigation 1988;6:7-14
27. Wesson MF, **Osborne MP**, Petrek J, Kinne D, McCormick B.
Iridium-192 implants for primary breast cancer: Experience with concomitant limited resection or re-excision
Endocurietherapy/Hyperthermia Oncology 1988;4:149-153
28. McCormick B, Wesson MF, Cox L, **Osborne MP**, Petrek JA, Kinne DW.
Iridium-192 implants for primary breast cancer: Experience with placement at the time of wide local excision
International Journal of Radiation Oncology, Biology and Physics 1988;15:745-748
29. Telang NT, Basu A, Kurihara H, **Osborne MP**, Modak MJ.
Modulation in the expression of murine mammary tumor virus, ras proto-oncogene and of alveolar hyperplasia by fatty acids in mouse mammary explant cultures
Anticancer Research 1988;8:971-976
30. **Osborne MP**, Karmali RA, Hershcopf RJ, Bradlow HL, Kourides IA, Williams WR, Rosen PP, Fishman J.
Omega-3 fatty acids: modulation of estrogen metabolism and potential for breast cancer prevention.
Cancer Investigation 1988;6:629-631
31. Dermatis H, Rowland J, Miransky J, Kerner J, **Osborne MP**, Holland J.
Consent and compliance in chemoprevention trials
Cancer Investigation 1988;6:633-635
32. Kinne DW, Petrek JA, **Osborne MP**, Fracchia AA, DePalo AA, Rosen PP.
Breast carcinoma in-situ
Archives of Surgery 1989;124:33-36

33. **Osborne MP**, Asina S, Wong GY, Old LJ, Cote RJ.
Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: a study of sensitivity in a model system
Cancer Research 1989;49:2510-2513
34. Telang NT, Bradlow HL, Kurihara H, **Osborne MP**.
In vitro biotransformation of estradiol by explant cultures of murine mammary tissues
Breast Cancer Research and Treatment 1989;13:173-181
35. Baron PL, Moore MP, Kinne DW, Candela FC, **Osborne MP**, Petrek JA.
Occult breast cancer presenting with axillary metastases: updated management
Archives of Surgery 1990;125:210-215
36. **Osborne MP**, Telang NT, Kaur S, Bradlow HL.
Influence of chemo-preventive agents, tamoxifen and hydroxyphenylretinamide (HPR) on estradiol metabolism and mammary preneoplasia in C3H mice.
Steroids 1990;55:114-119
37. Telang NT, Axelrod DM, Bradlow HL, **Osborne MP**.
Metabolic biotransformation of estradiol in human mammary explant cultures
Annals of the New York Academy of Sciences 1990;586:70-78
38. Telang NT, Basu A, Modak MJ, **Osborne MP**.
Cellular ras proto-oncogene expression in human mammary explant cultures: A potential marker for chemical carcinogenesis
Annals of the New York Academy of Sciences 1990;586:230-237
39. Telang NT, **Osborne MP**, Sweterlitsch LA, Narayanan R.
Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression
Cell Regulation 1990;1:863-872
40. Dershaw DD, McCormick B, Cox L, **Osborne MP**.
Differentiation of benign and malignant local tumor recurrence after lumpectomy
American Journal of Roentgenology 1990;155:35-38
41. Seres DS, Bunk MJ, **Osborne MP**, Rivlin RS, Tiwari RK.
Effects of marginal dietary zinc deficiency and vitamin E supplementation on hepatic adenine dinucleotide phosphoribosyl transferase activity in female Sprague-Dawley rats
Nutrition Research 1991;11:337-345
42. Telang NT, Axelrod DM, Wong GY, Bradlow HL, **Osborne MP**.
Biotransformation of estradiol by explant cultures of human breast tissue
Steroids 1991;56:37-43
43. Dershaw DD, Panicek DM, **Osborne MP**.
Significance of lymph nodes visualized by the mammographic axillary view
Breast Diseases 1991;4:271-280

44. Tiwari RK, Wong GY, Mukhopadhyay B, Telang NT, Liu J, Hakes TB, **Osborne MP**.
Interferon-alpha and gamma mediated gene responses in a human breast carcinoma cell line
Breast Cancer Research and Treatment 1991;18:33-41
45. **Osborne MP**, Asina S, Wong GY, Old LJ, Cote RJ, Rosen PP.
Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow
Cancer Research 1991;51:2706-2709
46. Telang NT, Narayanan R, Bradlow HL, **Osborne MP**.
Coordinated expression of intermediate biomarkers for tumorigenic transformation in ras-transfected mouse mammary epithelial cells
Breast Cancer Research and Treatment 1991;18:155-163
47. Cote RJ, Rosen PP, Lesser ML, Old LJ, **Osborne MP**.
Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
Journal of Clinical Oncology 1991;9:1749-1756
48. Telang NT, Kurihara H, Wong GY, Bradlow HL, **Osborne MP**.
Preneoplastic transformation in mouse mammary tissue: identification and validation of intermediate biomarkers for chemoprevention
Anticancer Research 1991;11:1021-1028
49. Michnovicz JJ, Telang NT, **Osborne MP**, Bradlow HL.
Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice
Carcinogenesis 1991;12:1571-1574
50. Tiwari RK, Mukopadhyay B, Telang NT, **Osborne MP**.
Modulation of gene expression by selected fatty acids in human breast cancer cells
Anticancer Research 1991;11:1383-1388
51. Tiwari RK, Wong GY, Liu I, Miller D, **Osborne MP**.
Augmentation of cytotoxicity using combinations of interferon (types I and II), tumor necrosis factor and tamoxifen in MCF-7 cells
Cancer Letters 1991;61:45-52
52. **Osborne MP**, Borgen PI, Wong GY, Rosen PP, McCormick B.
Salvage mastectomy for local-regional relapse after breast conserving surgery and radiation therapy
Surgery, Gynecology and Obstetrics 1992;174:189-194
53. **Osborne MP**, Ruperto JF, Crowe JP, Rosen PP, Telang NT.
The effect of tamoxifen on preneoplastic cell proliferation in N-nitroso-N-methylurea-induced mammary carcinogenesis
Cancer Research 1992;52:1477-1480
54. Narayanan R, Lawlor KG, Schaapveld RQJ, Cho KR, Vogelstein B, Tran PB-V, **Osborne MP**, Telang NT.
Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts
Oncogene 1992;7:553-561

55. Telang NT, Suto A, Wong GY, **Osborne MP**, Bradlow HL.
Induction by estrogen metabolite 16a-hydroxestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells
Journal of the National Cancer Institute 1992;84:634-636
56. Tiwari RK, Borgen PI, Cordon-Cardo C, **Osborne MP**.
HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
Anticancer Research 1992;12:419-426
57. Willard W, Borgen P, Bol R, Tiwari R, **Osborne MP**.
Cowden's Disease: A case report with analyses at the molecular level
Cancer 1992;69:2969-2974
58. Suto A, Bradlow HL, Wong GY, **Osborne MP**, Telang NT.
Persistent endocrine responsiveness of ras oncogene-transformed mouse mammary epithelial cells
Steroids 1992;57:262-268
59. Telang NT, Bradlow HL, **Osborne MP**.
Molecular and endocrine biomarkers in non-involved breast: relevance to cancer chemoprevention
Journal of Cellular Biochemistry 1992;16:161-169
60. Borgen PI, Vlamis V, Potter C, Hoffman B, Wong GY, Kinne DW, **Osborne MP**, McKinnon WMP.
Current management of male breast cancer: A review of 104 cases
Annals of Surgery 1992;215:451-459
61. Lawler KG, Telang NT, **Osborne MP**, Schaapveld RQ, Cho KR, Vogelstein B, Narayanan R.
Antisense RNA to the putative tumor suppressor gene "Deleted in Colorectal Cancer" transforms fibroblasts
Annals of the New York Academy of Sciences 1992;660:283-285
62. Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, **Osborne MP**, Rosen PP.
Breast cancer in patients irradiated for Hodgkin's disease: A clinical and pathological analysis of 45 events in 37 patients
Journal of Clinical Oncology 1992;10:1674-1681
63. Tiwari RK, Mukhopadhyay B, **Osborne MP**.
Desensitization of human breast cancer cells by interferon
International Journal of Oncology 1992;1:601-605
64. Dershaw DD, McCormick B, **Osborne MP**.
Detection of local recurrence after conservation therapy for breast carcinoma
Cancer 1992;70:493-496
65. Bradlow HL, Michnovicz JJ, Telang NT, **Osborne MP**, Goldin BR.
Diet, oncogenes and tumor viruses as modulators of estrogen metabolism in vivo and in vitro
Cancer Prevention and Detection 1992;16:1 S38-S42

66. Suto A, Bradlow HL, Kubota T, Kilajma M, Wong GY, **Osborne MP**, Telang NT.
Alterations in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor suppressing agents
Steroids 1993;58:215-219
67. Breuer B, Kash K, Rosenthal G, Diemer K, **Osborne MP**, Miller DG.
Reporting bilaterality status in first-degree relatives with breast cancer: A validity study
Genetic Epidemiology 1993;10:245-256
68. Tiwari RK, Guo L, Mukhopadhyay B, Wong GY, **Osborne MP**.
Gene induction by interferons in BT-20 cells
International Journal of Oncology 1993;481-487
69. Garg A, Suto A, **Osborne MP**, Gupta RC, Telang NT.
Expression of biomarkers for transformation in 7,12-dimethylbenz[a]anthracene-treated mammary epithelial cells
International Journal of Oncology 1993;3:185-189
70. Breuer B, Luo J, DeVivo I, Pincus M, Tatum AH, Daucher J, Minick R, **Osborne MP**, Miller DG, Nowak E, Cody H, Carney WP, Brandt-Rauf PW.
Detection of elevated c-erbB-2 oncoprotein in the serum and tissue in breast cancer.
Medical Science Research 1993;21:383-384
71. DeVivo I, Breuer B, Smith S, Milling C, Pincus M, Tatum AH, Daucher J, Niman H, Minick R, **Osborne MP**, Miller DG, Nowak E, Cody H, Brandt-Rauf PW.
Detection of serum c-myc oncoprotein in cancer patients by immunoblot
Medical Science Research 1993;21:345-347
72. **Osborne MP**, Bradlow HL, Wong GYC, Telang NT.
Upregulation of estradiol C16 α -hydroxylation in human breast tissue: A potential biomarker of breast cancer risk
Journal of the National Cancer Institute 1993;85:1917-1920
73. Suto A, Bradlow HL, Wong GYC, **Osborne MP**, Telang NT.
Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells
Breast Cancer Research and Treatment 1993;27:193-202
74. Tiwari RK, Guo L, Bradlow HL, Telang NT, **Osborne MP**.
Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent
Journal of the National Cancer Institute 1994;86:126-131

75. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I, **Osborne MP**.
Catechol estrogen production in rat microsomes after treatment with indole-3-carbinol, ascorbigen, or B-naphthaflavone: A comparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods
Steroids 1994;59:318-322
76. Telang NT, Bradlow HL, **Osborne MP**.
Effect of tamoxifen on mammary preneoplasia: Relevance to chemopreventive intervention
Cancer Detection and Prevention 1994;18:313-321
77. **Osborne MP**, Rosen PP.
Detection and management of bone marrow micrometastases in breast cancer
Oncology 1994;8:25-31
78. Kash KM, Holland JC, Miller DG, **Osborne MP**.
Psychological distress and adherence to screening behaviors in women at genetic risk for breast cancer
Psychosomatic Medicine 1994;56:148-149
79. Bradlow HL, Michnovicz JJ, Halper M, Miller DG, Wong GY, **Osborne MP**.
Long-term responses of women to indole-3-carbinol or a high fiber diet
Cancer Epidemiology Biomarkers and Prevention 1994;3:591-595
80. **Osborne MP**, Simmons RM.
Salvage surgery for recurrence after breast conservation
World Journal of Surgery 1994;18:93-97
81. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, Brody L, Friedman L, Ostermeyer E, Szabo C, King MC, Jharwar S, Offit K, Norton L, Gilewski T, Lubin M, **Osborne MP**, Black D, Boyd M, Steel M, Ingles S, Haile R, Lindblom A, Olsson H, Borg A, Bishop DT, Solomon E, Radice P, Spatti G, Gayther S, Ponder B, Warren W, Stratton M, Liu Q, Fujimura F, Lewis C, Skolnick M, Goldgar E.
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene
Journal of the American Medical Association 1995;273:535-541
82. Valdimarsdottir HB, Bovberg DH, Kash KM, Holland JC, **Osborne MP**, Miller DG.
Psychological distress in women with a familial risk of breast cancer
Psycho-Oncology 1995;4:133-141
83. Li G, **Osborne MP**, Tiwari RK.
Anti-proliferative effects of garlic constituents in cultured human breast cancer cells
Oncology 1995;2:787-791
84. Fishman J, **Osborne MP**, Telang NT.
The role of estrogen in mammary carcinogenesis.
Annals of the New York Academy of Sciences 1995;768:91-100
85. Araki R, Inoue S, **Osborne MP**, Telang NT.
Chemoprevention of mammary preneoplasia. In-vitro effects of a green tea polyphenol
Annals of the New York Academy of Sciences 1995;768:215-222

86. Kash KM, Holland JC, **Osborne MP**, Miller DG.
Psychological counseling strategies for women at risk of breast cancer
Journal of the National Cancer Institute, Monogr. 1995;17:73-79
87. Sepkovic DW, Bradlow HL, Ho G, Hankinson SE, Gong L, **Osborne MP**, Fishman J.
Estrogen metabolite ratios and risk assessment of hormone-related cancers. Assay
validation and prediction of cervical cancer risk
Annals of the New York Academy of Sciences 1995;768:312-316
88. Bradlow HL, Sepkovic DW, Telang NT, **Osborne MP**.
Indole-3-carbinol. A novel approach to breast cancer prevention
Annals of the New York Academy of Sciences 1996;768:180-200
89. **Osborne MP**.
Hormonal intervention in breast cancer: Past, present and future
Annals of the New York Academy of Sciences 1996;784:427-432
90. Arzimanoglou II, Lallas T, **Osborne MP**, Barber H, Gilbert F.
Microsatellite instability differences between familial and sporadic ovarian cancers
Carcinogenesis 1996;9:1799-1804
91. Bradlow HL, Telang NT, Sepkovic DW, **Osborne MP**.
2-Hydroxyestrone: the 'good' estrogen
Journal of Endocrinology 1996;150:S259-S265
92. Fishman JH, Gonzalez A, **Osborne MP**.
Breast cancer cells cultured in a system of new design presecrete an extracellular matrix and
proliferate within it without cell-cell adhesion
Biochemical and Biophysical Research Communication 1996;220:467-471
93. Bradlow L, Telang NT, **Osborne MP**.
Estrogen metabolites as bioreactive modulators of tumor initiators and promoters
Advances in Experimental Medical Biology 1996;387:285-296
94. Katdare M, Singhal H, Newmark H, **Osborne MP**, Telang NT.
Prevention of mammary preneoplastic transformation by naturally-occurring tumor inhibitors
Cancer Letters 1997;111:141-147
95. Telang NT, Katdare M, Bradlow HL, **Osborne MP**.
Estradiol metabolism: An endocrine biomarker for modulation of human mammary
Carcinogenesis
Environmental Health Perspectives 1997;105 Suppl:559-564
96. Singhal H, Potter C, **Osborne MP**.
No effect of timing of biopsy in the menstrual cycle on incidence of bone marrow
micrometastasis in patients with breast cancer
Annals of Surgical Oncology 1997; 4:503-505

97. Telang NT, Katdare M, Bradlow HL, **Osborne MP**, Fishman J.
Inhibition of proliferation and modulation of estradiol metabolism: Novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol
Proceedings of the Society for Experimental Biology and Medicine 1997; 216:246-252
98. Simmons RM, **Osborne MP**.
Dilemmas in breast disease: Prophylactic mastectomy
Breast Journal 1997;3:372-379
99. Zakowski SG, Valdimardottir HB, Bovbjerg DH, Borgen P, Holland J, Kash K, Miller DG, Mitnick J, **Osborne MP**, Van Zee K.
Predictors of intrusive thoughts and avoidance in women with family histories of breast cancer
Annals of Behavioral Medicine 1997;19:362-369
100. Bergstein I, Eisenberg LM, Bhalerao J, Jenkins NA, Copeland NG, **Osborne MP**
Bowcock AM, Brown AMC.
Isolation of two novel WNT genes, WNT 14 and WNT 15, one of which (WNT15) is closely linked to WNT3 on human chromosome 17q21
Genomics 1997;46:450-458.
101. Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, Haas B, **Osborne MP**, Norton L, Gilbert F, Offit K.
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
Genetic Testing 1997;1:47-51
102. Wong GYC, Bradlow L, Sepkovic D, Mehl S, Mailman J, **Osborne MP**.
Dose-ranging study of indole-3-carbinol for breast cancer prevention
Journal of Cellular Biochemistry 1997;Supplements 28/29:111-116
103. Telang NT, Inoue S, Bradlow HL, **Osborne MP**.
Negative growth regulation of oncogene-transformed mammary epithelial cells by tumor inhibitors.
Advances in Experimental Medicine and Biology 1997;400A:409-418
104. Gilbert F, Dabney MK, Diemer K, Ludwig S, Rosenthal G, **Osborne MP**.
BRCA1/BRCA2 mutations and breast cancer in Ashkenazi Jewish women
Annals of the New York Academy of Sciences 1997;833:198-203.
105. Davis DL, Telang NT, **Osborne MP**, Bradlow HL.
Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer
Environmental Health Perspectives 1997;105, Suppl3:571-576.
106. Telang NT, Arcuri F, Granata OM, Bradlow HL, **Osborne MP**, Castagnetta L.
Alteration of oestradiol metabolism in myc oncogene-transfected mouse mammary epithelial Cells
British Journal of Cancer 1998; 77:1549-1554

107. Bradlow HL, Sepkovic DW, Klug T, **Osborne MP**.
Application of an improved ELISA assay to the analysis of urinary estrogen metabolites
Steroids 1998; 63:406-413
108. Giess CS, Keating DM, **Osborne MP**, Ng YY, Rosenblatt R.
Retroareolar breast carcinoma: clinical, imaging, and histopathologic features
Radiology 1998; 207: 669-673
109. Breuer B, Smith S, Thor A, Edgerton S, **Osborne MP**, Minick R, Cody HS 3rd, Nowak E, Cortese A, Simmons RM, Carney WP, Brandt-Rauf PW.
ErbB-2 protein in sera and tumors of breast cancer patients
Breast Cancer Research Treatment 1998;49:261-70
110. Oliveria S, Christos PJ, Visintainer PF, McDougall CJ, **Osborne MP**.
Patterns of colon cancer screening among companies in the U.S.: A descriptive survey
American Journal of Health Promotion 1999;13:146 -148.
111. Jinno H, Steiner MG, Mehta RG, **Osborne MP**, Telang NT.
Inhibition of aberrant proliferation and induction of apoptosis in HER-2/*neu* oncogene transformed human mammary epithelial cells by *N*-(4-hydroxyphenyl) retinamide
Carcinogenesis 1999;20:229 -236.
112. Yagmur Y, Prasad MJ, **Osborne MP**.
Myofibroblastoma in the irradiated breast
Breast Journal 1999;5:136 -140.
113. Taioli E, Bradlow HL, Garbers VV, Sepkovic DW, **Osborne MP**, Trachman J, Ganguly S, Garte SJ.
Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk
Cancer Detection and Prevention 1999;23:232-237.
114. Giess CS, Keating DM, **Osborne MP**, Rosenblatt R.
Local tumor recurrence following breast-conservation therapy: Correlation of histopathologic findings with detection method and mammographic findings
Radiology 1999;212:829 -835.
115. Suto A, Telang NT, Tanino H, Takeshita T, Ohmiya H, **Osborne MP**, Kubota T.
In vitro and in vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites
Journal of the Japanese Breast Cancer Society 1999;6:87-92
116. Simmons RM, Fish SK, Gayle L, LaTrenta GS, Swistel A, Christos P, **Osborne MP**.
Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies
Annals of Surgical Oncology 1999;6:676-681
117. Simmons RM, **Osborne MP**.
The evaluation of high risk and pre-invasive breast lesions and the decision process for follow up and surgical intervention
Surgical Oncology 1999;8:55-65

118. Prasad ML, **Osborne MP**, Giri DD, Hoda SA.
Microinvasive carcinoma (T1mic) of the breast: Clinicopathologic profile of 21 Cases
American Journal of Surgical Pathology 2000;24:422-428.
119. Shin SJ, **Osborne MP**, Moore A, Hayes MK, Hoda SA.
Determination of size in invasive breast carcinoma: Pathologic considerations and clinical implications
American Journal of Clinical Pathology 2000;113:S19-29
120. Saqi A, **Osborne MP**, Rosenblatt R, Shin SJ, Hoda SA.
Quantifying mammary duct carcinoma in situ: A wild goose chase?
American Journal of Clinical Pathology 2000;113:S30-37
121. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, **Osborne MP**.
Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: Analysis in more than 900 patients
Journal of the American College of Surgeons 2000;191:1-8
122. Rivadeneira DE, Simmons RM, Fish SK, Gayle L, La Trenta GS, Swistel A, **Osborne MP**.
Skin-sparing mastectomy with immediate breast reconstruction: A critical analysis of local recurrence
Cancer Journal 2000;6:331-35
123. Telang NT, Katdare M, Bradlow HL, **Osborne MP**.
Cell cycle regulation, apoptosis and estradiol biotransformation: novel endpoint biomarkers for human breast cancer prevention
Journal of Clinical Ligand Assay 2000;23:130-137
124. Giess CS, Keating DM, **Osborne MP**, Mester J, Rosenblatt R.
Comparison of rate of development and rate of change for benign and malignant breast calcifications at the lumpectomy bed
American Journal of Roentgenology 2000;175:789-93.
125. Rosenbaum Smith SM, **Osborne MP**.
Breast cancer chemoprevention
American Journal of Surgery 2000;180:249-251
126. Simmons R, Hoda S, **Osborne MP**.
Bone marrow micrometastases in breast cancer patients
American Journal of Surgery 2000;180:309-312
127. Shaikh N, LaTrenta G, Swistel A, **Osborne MP**.
Detection of recurrent breast cancer after TRAM flap reconstruction
Annals of Plastic Surgery 2001; 47:602-607
128. Simmons RM, Brennan MB, Christos P, Sckolnick M, **Osborne MP**.
Recurrence rates in patients with central or retroareolar breast cancers treated with mastectomy or lumpectomy
American Journal of Surgery 2001; 182:325-329

129. Simmons RM, Smith SM, **Osborne MP**.
Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization
Breast Journal 2001; 7:181-183
130. Simmons R, Brennan M, Christos P, King V, **Osborne MP**.
Analysis of nipple/areolar involvement with mastectomy: Can the areola be preserved?
Annals of Surgical Oncology 2002; 9:165-168
131. Jinno H, Steiner MG, Nason-Burchenal K, **Osborne MP**, Telang NT.
Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells
International Journal of Oncology 2002; 21:127-134
132. Katdare M, **Osborne MP**, Telang NT
Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells
International Journal of Oncology 2002; 21:809-815
133. Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Eavns G, **Osborne MP**, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS
Oral Contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Journal of the National Cancer Institute 2002; 94:1773-1779
134. Hoda SA, Chiu A, Resetskova E, Harigopal M, Hoda RS, **Osborne MP**.
Pathological examination of sentinel lymph node in breast cancer: potential problems and possible solutions
Microscopy Research and Technique 2002; 15:85-91
135. Simmons R, Adamovich T, Brennan M, Christos P, Schultz M, Eisen C, **Osborne MP**
Nonsurgical evaluation of pathologic nipple discharge
Annals of Surgical Oncology 2003; 10:113-116
136. Simmons R, Thevarajah S, Brennan MB, Christos P, **Osborne MP**
Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization
Annals of Surgical Oncology 2003; 10:242-247
137. Hollenbeck ST, Cellini C, Christos P, Varnado-Rhodes Y, Martins D, Nussbaum M, **Osborne MP**, Simmons R.
Breast cancer in patients with residual invasive carcinoma is more accurately staged with additive tumor size assessment
Annals of Surgical Oncology 2004; 11:59-64
138. Sauven P, on behalf of the Association of Breast Surgery Family History Guidelines Panel (**Osborne MP** et al)
Guidelines for the management of women at increased familial risk of breast cancer
European Journal of Cancer 2004; 40:653-665

139. Yu JJ, Brennan M, Christos, P, **Osborne MP**, Hoda S, Simmons RM
Bone marrow micrometastases and adjuvant treatment of breast cancer
Breast Journal 2004; 10:181-185
140. Trocciola SM, Hoda S, **Osborne MP**, Christos PJ, Levin H, Martins D, Carson J, Daly J, Simmons RM
Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients?
Journal of the American College of Surgeons 2005; 200:720-726
141. Carter BJ, Birnbaum AS, Hark L, Vickery B, Potter C, **Osborne MP**
Using media messaging to promote healthful eating and physical activity among urban youth
Journal of Nutrition Education and Behavior 2005; 37:98-99
142. Hanasono MM, **Osborne MP**, Dielubanza EJ, Peters SB, Gayle LB
Radiation induced angiosarcoma after mastectomy and TRAM flap breast reconstruction
Annals of Plastic Surgery 2005; 54:211-214
143. Braun S, Vogl FD, Naume B, Janni W, **Osborne MP**, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga J-Y, Marth C, Ouzio D, Wiedswang G, Solomayer E-F, Kundt G, Strobl B, Fehm T, Wong GYC, Bliss J, Vincent-Salomon A, Pantel K
A pooled analysis of bone marrow micrometastasis in breast cancer
New England Journal of Medicine 2005; 353:793-802
144. Stearns V, Slack R, Greep N, Henry-Tilman R, **Osborne MP**, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, Hayes D, Isaacs C
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial
Journal of Clinical Oncology 2005; 23:6919-6930
145. Schwarz GS, Drotman M, Rosenblatt R, Milner L, Shamonki J, **Osborne MP**
Fibromatosis of the breast: case report and current concepts in the management of an uncommon lesion
Breast Journal 2006; 12:66-71
146. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, **Osborne MP**, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Hereditary Breast Cancer Clinical Study Group
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update
International Journal of Cancer 2006; 118:2281-2284

147. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, **Osborne M**, Sun P, Narod SA. Hereditary Breast Cancer Clinical Group Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
Breast Cancer Research 2006;8: Epub 2006 Mar 21
148. Huston TL, Pigalarga R, **Osborne MP**, Tousimis E
The influence of additional surgical margins on the total specimen volume excised and the reoperative rate after breast-conserving surgery
American Journal of Surgery 2006; 192:509-12
149. **Osborne MP**
William Stewart Halsted: His life and contributions to cancer
Lancet Oncology 2007; 8:256-65
150. Cheung K, Tam W, Chuang E, **Osborne MP**
Concurrent invasive ductal carcinoma and chronic lymphocytic leukemia manifesting as a collision tumor in the breast
Breast Journal 2007;13:413-17
151. Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domcheck S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group, Garber J, **Osborne M**, Fishman D, McLennan J, McKinnon W, Merajver S, Olsson H, Provencher D, Pasche B, Evans G, Meschino WS, Lemire E, Chudley A, Rayson D, Bellati C
Age at first birth and the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers
Breast Cancer Research and Treatment 2007; 105:221-228
152. Arora N, Martins D, Huston TL, Christos P, Hoda S, **Osborne MP**, Swistel AJ, Tousimis E, Pressman PI, Simmons RM.
Sentinel node positivity rates with and without frozen section for breast cancer.
Ann Surg Oncol. 2008;15:256-261
153. Arora N, Martins D, Ruggerio D, Tousimis E, Swistel AJ, **Osborne MP**, Simmons RM.
Effectiveness of a noninvasive digital infrared thermal imaging system in the detection of breast cancer.
American Journal of Surgery. 2008;196:523-526.
154. Vaidya J, **Osborne MP**
An uncommon (hepatic) scintiscan during sentinel node biopsy--an optical illusion.
International Journal of Surgery 2008; 6:422-423.

155. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA; **Hereditary Breast Cancer Clinical Study Group**.
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers
Journal of the National Cancer Institute 2008;100:1361-7157.
156. Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, **Osborne MP**, Boachie-Adjei K, Twardzik W, Tartter PI.
Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
American Journal of Surgery 2008;196:527-158.
157. Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group
Predictors of contralateral prophylactic mastectomy in women with a BRCA 1 or BRCA 2 mutation
Journal of Clinical Oncology 2008;26:1093-7
158. Jacobson AF, Asad J, Boolbol SK, **Osborne MP**, Boachie-Adjei K, Feldman SM
Do additional shaved margins at the time of lumpectomy eliminate the need for re-excision?
American Journal of Surgery 2008;196:556-8
157. Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA; **Hereditary Breast Cancer Clinical Study Group**
Predictors of contralateral prophylactic mastectomy in women with a BRCA 1 or BRCA 2 mutation
Journal of Clinical Oncology 2008;26:1093-7
158. Jacobson AF, Asad J, Boolbol SK, **Osborne MP**, Boachie-Adjei K, Feldman SM.
Do additional shaved margins at the time of lumpectomy eliminate the need for re-excision?
American Journal of Surgery 2008;196:556-8
159. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA; **Hereditary Breast Cancer Clinical Study Group**.
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
International Journal of Cancer 2008;122:2017-22
160. Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA; **Hereditary Breast Cancer Clinical Study Group**.
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.
Breast Cancer Research and Treatment 2009;114:127-35

161. Chadha M, Trombetta M, Boolbol S, **Osborne MP**.
Managing a small recurrence in the previously irradiated breast. Is there a second chance for breast conservation?
Oncology 2009;23:933-40
162. Ginsburg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA:
Hereditary Breast Cancer Clinical Study Group.
BRCA1 and BRCA2 families and the risk of skin cancer.
Familial Cancer. 2010;9:489-93
163. Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA;
Hereditary Breast Cancer Clinical Study Group.
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Journal of the National Cancer Institute 2010;102:1874-8
164. Dennis J, Ghadirian P, Little J, Lubinski J, Gronwald J, Kim-Sing C, Foulkes W, Moller P, Lynch HT, Neuhausen SL, Domchek S, Armel S, Isaacs C, Tung N, Sweet K, Ainsworth P, Sun P, Krewski D, Narod S; **Hereditary Breast Cancer Clinical Study Group**.
Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers.
Breast. 2010;19:479-83
165. Pal T, Keefe D, Sun P, Narod SA; **Hereditary Breast Cancer Clinical Study Group**.
Fertility in women with BRCA mutations: a case-control study.
Fertil Steril. 2010;93:1805-8
166. Chuang E, Christos P, Flam A, McCarville K, Forst M, Shin S, Vahdat L, Swistel A, Simmons S, **Osborne M**, Moore A, Mazundar, M, Klein P.
Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group
Journal of Immigrant and Minority Health (in press) 2012

Non Peer Reviewed Publications

1. **Osborne MP**
Drug Addiction
Charing Cross Hospital Gazette 1969;128-130
2. **Osborne MP**
Three unusual cases presenting with abdominal swelling
Charing Cross Hospital Gazette Clinical and Scientific Supplement No. II. 1970;5-14
3. **Osborne MP**, Sanderson FM.
High serum acid phosphatase levels (letter)
Lancet 1973;ii:802
4. **Osborne MP**
Diseases of the breast
Monthly Index of Medical Specialties 1978;275-285
5. **Osborne MP**
The scope of surgical oncology (editorial)
Clinical Oncology 1979;3:199-200
6. **Osborne MP**, Ryman BE, Payne JH, McCready VR.
The use of ^{99m}Tc-labelled neutral liposomes in lymphoscintigraphy: a comparison of scintigram interpretations with node histology in a series of breast cancer patients
In: Progress in Radiopharmacology.
Ed: PM Cox. Elsevier / North Holland Biomedical Press 1981;2:317-325
7. **Osborne MP**, Meijer WS, Yeh DJ, DeCosse JJ.
Lymphoscintigraphy in the staging of solid tumors
Surgery, Gynecology and Obstetrics 1983;158:384-391
8. **Osborne MP**
Controversies in the management of primary breast cancer
Cancer Investigation 1983;1:259-265
9. Recabaren J, **Osborne MP**, DeCosse JJ.
Individuals at High Risk - Preventive Measures
In: Series: New Horizons in Oncology. Ed: B Stoll. Vol 3: Risk Factors in Multiple Cancer.
Wiley, London, 198, pp 263-275.
10. **Osborne MP**
Limited resection and radical radiation therapy in the treatment of early stage breast cancer.
Problems in General Surgery 1985;2:159-166
11. **Osborne MP**, Crowe JP
The identification of enhanced risk patients and their management in a special surveillance breast clinic
In: Breast Cancer: Diagnosis and Treatment. Eds: IM Ariel, JB Cleary. McGraw Hill, New York, 1987, pp75-86.

12. **Osborne MP**
The biological basis for breast cancer treatment options
American College of Surgeons Bulletin 1986;7:4-14
13. **Osborne MP**, Andrakis C, Nonkin R
The thermal scalpel: A comparative study with the conventional scalpel and the electrocautery.
Contemporary Surgery 1986;29:51-54
14. **Osborne MP**
Breast development and anatomy
In: Breast Diseases. Eds. J Harris, S Hellman, C. Henderson, D Kinne. Lippincott, Philadelphia
1987, pp 1-14.
15. Williams WR, **Osborne MP**
Familial aspects of breast cancer: An overview
In: Breast Diseases. Eds: J Harris, S Hellman, C Henderson, D Kinne. Lippincott, Philadelphia
1987, pp 109-120.
16. **Osborne MP**
Prophylactic mastectomy
In: Breast Diseases. Eds: J Harris, S Hellman, C Henderson, D Kinne. Lippincott, Philadelphia 1987, pp 120-121.
17. **Osborne MP**, Bayle J-C
Prophylactic mastectomy: Rarely indicated in the non-affected patient
Primary Care and Cancer 1988;8:25-31
18. **Osborne MP**, Axelrod DM
Control of local infection and necrosis
In: Manual of Oncologic Therapeutics. Ed: RE Wittes. Lippincott, Philadelphia 1989-1990, pp 550-56.
19. **Osborne MP**, Axelrod DM
The swollen extremity
In: Manual of Oncologic Therapeutics. Ed: RE Wittes. Lippincott, Philadelphia 1989-1990, pp 565-68.
20. **Osborne MP**
Sarcoma of the breast
In: Surgical Management of Soft Tissue Sarcoma. Eds: MH Shiu, MF Brennan. Lea and Febiger, Philadelphia 1989, pp 216-234.
21. Telang NT, Bockman RS, Modak MJ, **Osborne MP**
The role of fatty acids in murine and human mammary carcinogenesis: An in vitro approach
In: Carcinogenesis and Dietary Fat. Eds: S Abraham, L Marnett, K Hohn. Kluwer Academic Publishers, Boston 1989, pp 427-451.

22. Dershaw DD, **Osborne MP**
Clinical aspects of imaging techniques in breast cancer
Seminars in Surgical Oncology 1989;5:82-93
23. **Osborne MP**, Hundahl SA, Urban JA
Radical surgery: Rationale, indications and techniques
In: Current Treatment of Cancer: Breast Cancer. Eds. B Hoogstraten, I Burn, HJG Bloom.
UICC, Springer-Verlag, Berlin 1989, pp 133-160
24. **Osborne MP**, Borgen PI
The role of mastectomy in the treatment of breast cancer
Surgical Clinics of North America 1990;70:1023-1046
25. **Osborne MP**
Small-size breast cancer (3 cm. mass). When is conservative therapy not appropriate
In: Common Problems in Cancer Surgery. Ed: H Wanebo. Year Book Medical Publishers,
Chicago 1990, pp 24-29
26. **Osborne MP**
Intermediate-size breast cancer When is breast conservation not indicated?
In: Common Problems in Cancer Surgery. Ed: H Wanebo. Year Book Medical Publishers,
Chicago 1990, pp 30-34
27. **Osborne MP**, Telang NT
Primary prevention of breast cancer.
In: The Breast: Comprehensive Management of Benign and Malignant Diseases.
Eds: KI Bland, EM Copeland. WB Saunders, Philadelphia 1991, pp 246-261
28. Telang NT, Basu A, Modak MJ, Bradlow HL, **Osborne MP**
Fatty acid-induced modulation of carcinogenesis in human and murine mammary explant
cultures
In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Eds: KV Honn,
LJ Marnett, S Nigam, T Walden. Kluwer Academic Publishers, Boston 1991;15:93-102
29. Axelrod DM, **Osborne MP**
Control of infection and necrosis
In: Manual of Oncologic Therapeutics. Ed: RE Wittes. Lippincott, Philadelphia 1991-1992,
pp 395-402
30. Axelrod DM, **Osborne MP**
The swollen extremity
In: Manual of Oncologic Therapeutics. Ed: RE Wittes. Lippincott, Philadelphia 1991-1992,
pp 405-407
31. Cote RJ, Rosen PP, Old LF, **Osborne MP**
Detection of bone marrow micrometastases in patients with early-stage breast cancer
Diagnostic Oncology 1991;1:37-42

32. **Osborne MP**
Salvage mastectomy.
Seminars in Surgical Oncology 1991;7:291-295
33. **Osborne MP**
Breast development and anatomy
In: Breast Diseases, 2nd Edition. Eds: J Harris, S Hellman, C Henderson, D Kinne.
Lippincott, Philadelphia 1991, pp 1-13
34. Bradlow HL, **Osborne MP**, Michnovicz JJ, Telang NT
Modulation of estrogen metabolism: Possible application to the chemo-prevention of breast cancer
In: Hormonal Carcinogenesis. Eds: JJ Li, S Nardi, SA Li. Springer-Verlag, New York 1992, pp 89-111
35. Telang NT, **Osborne MP**
Ras oncogene: A novel molecular biomarker for breast cancer susceptibility and prevention
In: Current Perspectives on Molecular and Cellular Oncology. Ed: DA Spandidos. JAI Press Ltd., London 1992, pp 95-117
36. Telang NT, Basu A, Wong GY, Bradlow HL, **Osborne MP**
Chemopreventive modulation of human mammary carcinogenesis by bioactive lipids
In: Proceedings of II International Conference on Eicosanoids and other Bioactive Lipids in Cancer.
Eds: S Nigam, KV Hunn, LJ Marrell, TL Walden. Kluwer Academic Publishers, Boston 1992, pp 439-446
37. **Osborne MP**, Borgen PI
Atypical ductal and lobular hyperplasia and breast cancer risk.
Surgical Oncology Clinics of North America 1993;2: 1-11
38. Brady MS, **Osborne MP**
The biological basis of breast cancer treatment
Surgical Rounds 1993;16:27-33
39. **Osborne MP**, Hoda S
Current management of lobular carcinoma in situ of the breast
Oncology 1994;8:45-49
40. Whalen GF, **Osborne MP**
Breast cancer: The oncologic surgeon's perspective
In: Aesthetic Plastic Surgery, 2nd Edition. Eds: TD Rees, GS LaTrenta. WB Saunders, Philadelphia 1994, pp 1050-1061
41. Axelrod DM, **Osborne MP**
The swollen extremity
In: Manual of Oncologic Therapeutics. JB Lippincott, Philadelphia 1995, pp 452-455

42. **Osborne MP**
Breast Development and Anatomy
In: Diseases of the Breast, Eds: J Harris, M Lippman, M Morrow, S. Hellman. 2nd Edition
Lippincott. Philadelphia 1996, pp 1-14
43. Oliveria SA, **Osborne MP**
Diet, breast cancer and case-control studies
Lancet 1996;347:1346
44. Davis DL, Axelrod D, **Osborne MP**, Telang NT
Environmental influences on breast cancer risk
Science & Medicine May/June 1997; 56-63
45. **Osborne MP**
Ethical dilemmas of BRCA testing in breast cancer
Cancer Case Presentations: The Tumor Board 1997;1:11
46. **Osborne MP**, Boyle P, Lipkin M
Cancer prevention.
Lancet 1997; 349 (suppl. II):27-30
47. **Osborne MP**
Breast cancer gene testing: Pain or gain? (editorial)
Contemporary Surgery 1997;60:312
48. Bradlow HL, Davis D, Sepkovic DW, Tiwari R, **Osborne MP**
Role of the estrogen receptor in the action of organochlorine pesticides on estrogen metabolism in human breast cancer cell lines
The Science of the Total Environment 1997;208: 9-14
49. Simmons RM, **Osborne MP**
Treatment of recurrent ductal carcinoma in situ
In: Ductal Carcinoma In Situ of the Breast. Ed: MJ Silverstein. Williams & Wilkins, Baltimore, Maryland 1997, pp 569-575
50. Katdare M, **Osborne MP**, Telang NT
Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals
Oncology Reports 1998;5:311-315
51. Simmons RM, **Osborne MP**
Surgical treatment of minimal breast cancer.
In: Early breast cancer. Eds: MWE Morgan, R Warren, G Querci della Rovere. Harwood Academic Publishers, Singapore 1998, pp 205-213
52. Prasad ML, **Osborne MP**, Hoda SA
Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast.
In: Anatomic Pathology 1998, Vol. Three. Eds: RE Fechner, PP Rosen. ASCP Press, Chicago, 1998, pp 209-232

53. Reichman BS, **Osborne MP**
Detection of occult micrometastatic disease
In: The Breast. Comprehensive management of benign and malignant diseases
Eds: KI Bland, EM Copeland. WB Saunders, Philadelphia 1998, pp 1299-1303
54. Benson JR, **Osborne MP**
Breast cancer therapy.
Lancet (Letter) 1998;351:145
55. Robertson J, Howell A, **Osborne MP**
Is tamoxifen of value in patients who have received breast conservation for localized DCIS?
Breast Cancer On-Line www.bco.org 1999.
56. **Osborne MP**
Chemoprevention of breast cancer
Surgical Clinics of North America 1999; 79:1207-1221
57. Benson JR, **Osborne MP**
Angiosarcoma in BRCA1 and 2 carriers
Breast Cancer Research and Treatment (Letter) 1999;55:293.
58. **Osborne MP**
Breast cancer prevention by antiestrogens
Annals of the New York Academy of Sciences 1999;889:146-151
59. **Osborne MP**
Forward to The Breast Cancer Prevention Diet.
Au. R Arnot. Little Brown & Co. 1999
60. **Osborne MP**
Breast development and anatomy
In: Diseases of the Breast, 2nd Edition. Eds: J Harris, M Lippman, M Morrow, S Hellman, MP Osborne.
Lippincott, Philadelphia 1999, pp 1-31.
61. Katdare M, Jinno H, **Osborne MP**, Telang NT
Negative growth regulation of oncogene-transformed human breast epithelial cells by phytochemicals: role of apoptosis.
Annals of the New York Academy of Science 1999;889:247-252
62. Bradlow HL, Sepkovic DW, Telang NT, **Osborne MP**
Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent
Annals of the New York Academy of Sciences 1999;889:204-213
63. Bradlow HL, Telang NT, Sepkovic DW, **Osborne MP**
Phytochemicals as modulators of cancer risk. Advances in Nutrition and Cancer 2.
Ed: Zappia et al. Kluwer Academic / Plenum Publishers, New York, 1999

64. **Osborne M**
Micrometastatic cancer in bone marrow: A predictor of prognosis.
XI International Congress of Senology. Eds Basurto CS, Cwilich RG, Forgach ES
Cancun, Mexico, May 13-18, 2000, p43.
65. Singhal H, **Osborne M**
Bone marrow micrometastases detection and significance In: Cancer metastasis, molecular and cellular mechanisms and clinical intervention. Eds. WG Jiang, RE Mansel. Kluwer Academic Publishers, Dordrecht, The Netherlands, 2000, pp 215-224.
66. Kash KM, Ortega-Verdejo K, Dabney MK, Holland JC, Miller DG, **Osborne MP**
Psychosocial aspects of cancer genetics: Women at high risk for breast and ovarian cancer. Seminars in Surgical Oncology 2000;18:333-338.
67. Gaynor M, Hayes MK, **Osborne MP**
Management of a patient with Stage IIA (T1N1M0) breast cancer
Breast Cancer online www.bco.org 2000; volume 3
68. Rosenbaum Smith SM, **Osborne MP**
Screening for breast cancer
In: Current Surgical Therapy 7th Edition. Ed: Cameron JL, Mosby, St. Louis 2001, pp 693-69
69. Simmons R, **Osborne MP**
Bone marrow aspiration as an adjunct to staging by sentinel lymph node biopsy in breast cancer patients
Seminars in Breast Disease 2002; 5:47-52
70. Simmons R, **Osborne MP**
Diseases of the breast
In Conn's Current Therapy Eds: Rakel RE and Bope ET: 2003; 1125-1130
71. **Osborne MP**
Prophylactic mastectomy
In Seminars in Breast Disease 2003; 6:34-40
72. Katdare M, **Osborne MP**, Telang NT
Novel cell culture models for prevention of human breast cancer
International Journal of Oncology 2003; 22:509-515
73. Simmons R, **Osborne MP**
Diseases of the breast
In Conn's Current Therapy Eds: Rakel RE and Bope ET: 2004 ; 1093-1099
74. **Osborne MP**
Breast anatomy and development.
In: Diseases of the Breast, 3rd Edition. Eds: J Harris, M Lippman, M Morrow, C Osborne, MP Osborne.
Lippincott, Philadelphia 2004, pp 3-14

75. **Osborne MP**, Huston TL
Evaluation and staging the patient with breast cancer
In: Breast Cancer, 2nd Edition. Ed: DF Roses
Elsevier Churchill Livingstone
Philadelphia 2005, pp 309-318

76. Vaidya JS, **Osborne M**
An uncommon (hepatic) scintiscan during sentinel node biopsy – An optical illusion
International Journal of Surgery 2008;6:422-423

77. Tousimis E, **Osborne MP**
Diseases of the breast
In: Conn's Current Therapy Eds: Rakel RE and Bope ET: 2007

78. **Osborne MP**, Boolbol S
Breast anatomy and development.
In: Diseases of the Breast, 4th Edition. Eds: J Harris, M Lippman, M Morrow, C Osborne
Lippincott, Philadelphia 2009

79. **Osborne MP**, Asad, J
Benign Breast Disease
In: Kuerer's Breast Surgical Oncology Ed: H Kuerer
McGraw Hill, New York 2010

Abstracts

1. **Osborne MP**, Jewkes R, Jeyasingh K, Vincenti AC, Burn JI.
Internal mammary lymph node scanning in the staging of breast cancer.
Clinical Oncology 1978;4:393
2. **Osborne MP**, Jeyasingh K, Richardson VJ, Vincenti AC, Jewkes RF, Burn JI.
The detection of lymph node metastases using radio-labeled colloids.
British Journal of Surgery 1978;65:354
3. Richardson VJ, **Osborne MP**, Jeyasingh K, Ryman BE, Burn JI.
Differential localization of ^{99m}Tc -technetium labeled liposomes in normal and tumor bearing lymph nodes of the rat.
British Journal of Cancer 1978;38:177
4. Jeyasingh K, Jewkes RF, Richardson VJ, **Osborne MP**, Ryman BE.
In-vivo distribution of ^{99m}Tc liposomes.
European Journal of Nuclear Medicine 1979;4:134
5. **Osborne MP**, Richardson VJ, Payne JH, McCready VR, Ryman BE.
Technetium-99m labeled liposome axillary lymphoscintigraphy in breast cancer.
Clinical Oncology 1980;6:289
6. **Osborne MP**.
The preoperative detection of internal mammary lymph node metastases in breast cancer.
Current Surgery 1981;38:31
7. Jeyasingh K, **Osborne MP**, Jewkes RF.
Detection of lymph node metastasis by a sequential scanning technique using two ^{99m}Tc -labelled colloids.
In: Nuklear Medezin. Functional Analysis. Ed. FK Schattauer, 19th International Meeting of SNME, Bern, Switzerland. Verlag, New York, 1981
8. **Osborne MP**, Griffiths JD, Shaw HJ.
Colon transposition in the management of upper gastrointestinal tract cancer.
Society of Surgical Oncology 34th Annual Meeting, Boston, MA 1981
9. Bolton JS, **Osborne MP**, Menendez-Botet C, Schwartz MK, Rosen PP, Kinne DW.
Estrogen receptor protein negative progesterone receptor protein positive primary breast cancer.
13th UICC International Cancer Conference, Seattle, WA 1982
10. Fracchia AA, Cody HS, Eisenberg BL, **Osborne MP**, Owens JC, Cody S, Caron AS, Urmacher C, Rosen PP, Bretsky S.
Stage II carcinoma of the breast: A detailed evaluation
13th UICC International Cancer Conference Seattle, WA 1982

11. **Osborne MP**, Rosen PP, Lesser ML, Schwartz MK, Menendez-Botet C, Fishman J, Kinne DW.
The relationship between family history, exposure to exogenous hormones and estrogen receptor protein in breast cancer
Society of Surgical Oncology 35th Annual Meeting, Marco Island, FL 1982
12. Meijer WS, **Osborne MP**, Yeh DJ, Bradlow HL.
Biokinetics of ^3H -estradiol in mature female mice and specific uptake of ^{125}I -estradiol in mature rats bearing transplanted mammary (MT/W9) carcinomas.
Proceedings of the American Association for Cancer Research 1983;24:174
13. Menendez-Botet CJ, Bolton JS, **Osborne MP**, Rosen PP, Schwartz MK.
Estrogen receptor protein negative, progesterone receptor protein positive primary breast cancer. Clinical Chemistry 1983;29:1231-1232
14. **Osborne MP**, Ormiston N, Harmer CL, McKinna JA, Baker J, Greening WP.
Early breast cancer: 20-year follow-up of breast conservation.
Society of Surgical Oncology 36th Annual Meeting Denver, CO 1983
15. Recabaren J, **Osborne MP**, Rosen PP, Chaganti R, Kinne DW, DeCosse JJ.
A special surveillance breast clinic: analysis of risk factors.
Proceedings of the American Society of Clinical Oncology 1984;3:6
16. Menendez-Botet CJ, Collin C, **Osborne MP**, Rosen PP, Schwartz MK.
Effect of local anesthesia (Lidocaine) and saline on the estrogen and progesterone receptor protein in breast tissue.
Clinical Chemistry 1984;30:941
17. **Osborne MP**, Rosen PP, Fry W, Meijer WS, DeCosse JJ.
Transplantation of human paraneoplastic breast lobules in nude mice: a potential model for chemoprevention studies.
Proceedings of the American Association for Cancer Research 1984;25:51
18. **Osborne MP**, Bradlow HL, Hershcopf R, Fishman J.
A potential marker for the risk of breast cancer: abnormal estradiol 16-alpha-hydroxylation.
Society of Surgical Oncology 37th Annual Meeting, New York, NY 1984
19. Crowe J, Rosen PP, Cupo S, DeCosse JJ, **Osborne MP**.
Response of transplanted human breast lobules to physiologic levels of estradiol.
Proceedings of the American Association for Cancer Research 1986;27:229
20. Axelrod DM, Telang NT, Rosen PP, **Osborne MP**.
Long-term survival of benign human mammary terminal duct lobular units in a chemically-defined, serum-free medium.
Proceedings of the American Association for Cancer Research 1986;27:30
21. Axelrod DM, Telang NT, Bradlow HL, **Osborne MP**.
In vitro metabolism of estradiol in human breast epithelium.
Breast Cancer Research and Treatment 1986;8:108

22. Telang NT, Basu A, Modak MJ, **Osborne MP**.
Modulatory influence of fatty acids on induction and promotion of preneoplasia in adult mouse mammary gland organ cultures.
FASEB Proceedings 1987;46:582
23. **Osborne MP**, Ruperto JF, Deschner EE, Cupo SH.
N-nitroso-N-methylurea-induced mammary carcinogenesis. The effect of tamoxifen on preneoplastic cell proliferation.
Proceedings of the American Association for Cancer Research 1987;28:136
24. Telang NT, Kurihara H, Bradlow HL, **Osborne MP**.
Metabolic transformation of estrogen in mouse mammary explant cultures: a potential metabolic marker for identification of risk for mammary cancer.
Proceedings of the American Association for Cancer Research 1987;28:237
25. Rowland J, Dermatis H, Kerner J, Tross S, Miransky J, **Osborne MP**, Holland J.
Psychosocial factors affecting consent to a breast cancer chemoprevention program.
Proceedings of the American Society of Clinical Oncology 1987;6:226
26. Axelrod DM, Bockman RS, Wong GY, **Osborne MP**, Kinne DW, Brennan MF.
A retrospective review of primary hyperparathyroidism in breast cancer patients
Proceedings of the American Society of Clinical Oncology 1987;6:65
27. Cote R, Rosen PP, **Osborne MP**, Sedira M, Hakes T, Kinne D, Old L.
Monoclonal antibodies (Mab) detect occult bone marrow metastases in operable breast cancer.
Laboratory Investigation 1987;56:16
28. Telang NT, Basu A, Kurihara H, Axelrod DM, Modak MJ, **Osborne MP**.
Molecular effects of chemical carcinogens on explant cultures of human mammary terminal duct lobular units.
Breast Cancer Research and Treatment 1987;10:91
29. **Osborne MP**, Rosen PP, Cox L, Kinne DW, Hellman S.
The margins of resection of the primary tumor in breast conservation.
Breast Cancer Research and Treatment 1987;10:106
30. **Osborne MP**, Telang NT, Kurihara H, Bradlow HL.
Risk-enhanced metabolism of estradiol in explant cultures of human benign mammary tissue.
Proceedings of the American Association of Cancer Research 1988;29:236
31. Telang NT, Basu A, Kurihara H, Axelrod DM, Modak MJ, **Osborne MP**.
Chemical carcinogen-mediated enhancement of ras proto-oncogene expression in benign human mammary tissue.
Proceedings of the American Association of Cancer Research 1988;29:466

32. Hershcopf RJ, Fishman J, Bradlow HL, Karmali L, Michnovicz JJ, Lustig RH, Stofberg P, **Osborne MP**.
Extent of estrogen 16-alpha-hydroxylation correlates with dietary saturated fat in women.
Endocrine Society 70th Annual Meeting Abstracts 1988;#1332
33. Telang NT, Basu A, Modak MJ, Bradlow HL, **Osborne MP**.
Parallel enhancement of ras proto-oncogene expression and of estradiol 16-alpha-hydroxylation in human mammary terminal duct-lobular units (TDLU) by a carcinogen.
Breast Cancer Research and Treatment 1988;12:138
34. Tiwari RK, Kurihara H, Telang NT, Hakes TB, **Osborne MP**.
Molecular determinants of the antiproliferative effect of interferon-alpha (IFN-alpha) and interferon-gamma (IFN-gamma) in human breast carcinoma.
Breast Cancer Research and Treatment 1988;12:146
35. **Osborne MP**, Cote RJ, Hakes TB, Kinne DW, Old LJ, Rosen PP.
Fluorescent monoclonal antibody detection of occult micrometastases in the bone marrow of patients with breast cancer.
Cancer Investigation 1988;6:565
36. Roush G, Pero R, **Osborne MP**, Halper M, Miller DG.
Breast Cancer and adenosine diphosphate ribosyl transferase (ADPRT) in white blood cells.
American Society of Preventive Oncology, Bethesda MD, 1988
37. **Osborne MP**, Asina S, Wong G, Old L, Cote RJ.
The sensitivity of immunofluorescent monoclonal antibody detection of breast cancer micrometastases in bone marrow.
European Journal of Cancer 1989;15:186
38. Tiwari RK, Rossi JD, Telang NT, **Osborne MP**.
Molecular response of human breast carcinoma cells to interferon-alpha.
Proceedings of the American Association for Cancer Research 1989;30:44
39. Telang NT, Basu A, Modak MJ, Bradlow HL, **Osborne MP**.
Fatty acid-induced modulation of molecular and metabolic markers of chemical carcinogenesis in human mammary explant cultures.
Proceedings of the American Association for Cancer Research 1989;30:694
40. **Osborne MP**, Telang NT, Wong GY, Modak MJ, Bradlow HL.
Breast cancer dependent elevation in the constitutive ras proto-oncogene expression and estradiol (E₂) 16-alpha-hydroxylation in benign human mammary tissue: Modulation by fatty acids.
Proceedings of the American Association for Cancer Research 1989;30:900
41. Dermatis H, Tross S, Rowland J, Kerner J, **Osborne MP**, Holland J.
Psychosocial factors associated with breast cancer screening in women at enhanced risk for breast cancer.
Proceedings of the American Society of Clinical Oncology 1989;8:23

42. Kash K, Dermatis H, Tross S, Rowland J, Holland J, **Osborne MP**.
The role of breast cancer risk status in preventive health behaviors of women who seek breast cancer screening.
Proceedings of the American Society of Clinical Oncology 1989;8:51
43. Telang N, Narayanan R, Sweterlitsch L, Bradlow HL, **Osborne MP**.
Molecular, metabolic and cellular determinants of oncogene-induced transformation in mammary epithelial cells.
Breast Cancer Research and Treatment 1989;14:168
44. **Osborne MP**, Asina S, Wong GY, Cote RJ, Rosen PP.
Sensitivity of immunocytochemical detection of breast cancer in bone marrow using monoclonal antibodies.
Breast Cancer Research and Treatment 1989;14:162
45. **Osborne MP**, Asina S, Wong GY, Rosen PP, Fracchia AA, Kinne DW, Cote RJ.
Immunofluorescent monoclonal antibody detection of breast cancer micrometastases.
Breast Cancer Research and Treatment 1989;14:161
46. Tiwari RK, Rossi JD, **Osborne MP**.
A distinct kinase regulates the induction of IFN inducible genes in human breast carcinoma cells.
Breast Cancer Research and Treatment 1989;14:171
47. Tiwari RK, Wong GY, Miller D, Telang N, **Osborne MP**.
Synergistic actions of interferons (IFNs) tumor necrosis factors (TNF) and tamoxifen (TAM) in MCF-7 cells.
Breast Cancer Research and Treatment 1989;14:153
48. Dershaw DD, McCormick B, Cox L, **Osborne MP**.
Benign disease mimicking local tumor recurrence after conservative treatment for breast carcinoma.
Radiological Society of North America Annual Meeting, Chicago, IL 1989
49. Telang N, Basu A, Wong GY, Modak MJ, Bradlow HL, **Osborne MP**.
In vitro modulation of mammary carcinogenesis by selected fatty acids.
Proceedings of the American Association for Cancer Research 1990;31:119
50. Tiwari RK, Mukhopadhyay B, Wong GY, **Osborne MP**.
Correlation of gene induction with the antiproliferative effect of interferons (IFNs) in BT-20 cells.
Proceedings of the American Association for Cancer Research 1990;31:80
51. Borgen PI, Tiwari RK, Rossi J, Wong GY, **Osborne MP**.
Amplification of HER-2/neu oncogene is associated with early metastasis in human breast cancer.
Proceedings of the American Association for Cancer Research 1990;31:313

52. Brady MS, Russo P, Perez G, Telang N, **Osborne MP**.
Detection of testosterone-repressed message-2 (TRPM) gene expression in MCF-7 cells in vitro following exposure to high dose estrogen.
Proceedings of the American Association for Cancer Research 1990;31:214
53. Kash KM, Holland J, **Osborne MP**.
Surveillance behaviors in women with a family history of breast cancer.
Proceedings of the American Society of Clinical Oncology 1990;9:306
54. Hakes T, Menendez-Botet C, Moore M, **Osborne MP**.
Modulation of estrogen (ER) and progesterone (PR) receptors in human breast cancer by alpha-2B interferon.
Proceedings of the American Society of Clinical Oncology 1990;9:44
55. **Osborne MP**, Cote RJ, Asina S, Wong GY, Potter C, Killackey D, Rosen PP.
Immunofluorescent monoclonal antibody detection of bone marrow micrometastases in patients with unilateral stages I-III invasive breast cancer.
Breast Cancer Research and Treatment 1990;16:194
56. Tiwari RK, Mukhopadhyay B, Telang NT, **Osborne MP**.
Interactions of fatty acids and interferons in breast cancer cells.
Breast Cancer Research and Treatment 1990;16:187
57. Telang N, Narayanan R, Wong GY, Bradlow HL, **Osborne MP**.
Oncogene-induced tumorigenic transformation of mammary epithelial cells is associated with altered estrogen metabolism.
Breast Cancer Research and Treatment 1990;16:148
58. Massie MJ, Jean LG, Kash KM, Griffin AM, **Osborne MP**.
Psychiatric evaluation of women at high risk for breast cancer who consider prophylactic mastectomy. Fifteenth International Cancer Congress.
Journal of Cancer Research and Clinical Oncology Supplement 1990;1190:25
59. Wong GY, Telang N, **Osborne MP**.
A statistical method for analyzing effects of oncogene transfection in fastidious epithelial cells.
Recent Developments in Statistical Research 1990:41 #45
60. **Osborne MP**, Borgen PI, Wong GY, Rosen PP, McCormick B.
Salvage mastectomy for local-regional recurrence after breast conserving surgery and radiation therapy.
Society of Surgical Oncology 43rd Annual Meeting, Washington, DC 1990
61. Borgen PI, Wong GY, Jyothi SM, Huvos AG, **Osborne MP**.
Atypical epithelial hyperplasia and breast cancer risk.
Society of Surgical Oncology 43rd Annual Meeting, Washington, DC 1990
62. Miller DG, **Osborne MP**.
A national high risk registry: A model for a collaborative resource.
American Society of Preventive Oncology, Bethesda MD, 1990

63. Cote RJ, Rosen PP, Lesser ML, **Osborne MP**.
Detection of occult bone marrow micrometastases in patients with operable breast cancer predicts early recurrence.
Modern Pathology 1990;3:23
64. **Osborne MP**, Borgen PI, Wong GY, Ghosssein N, Pressman P, Gump F, McCormick B.
Salvage mastectomy for local-regional recurrence after breast conserving surgery and radiation therapy. American Radium Society 75th Annual Meeting, Montreal, Canada 1991
65. Suto A, Telang NT, Wong GY, Bradlow HL, **Osborne MP**.
Persistent endocrine responsiveness of oncogene-transformed mouse mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1991;32:208
66. Telang N, Wong GY, Bradlow HL, **Osborne MP**.
Estradiol C16-alpha-hydroxylation: an endocrine biomarker for carcinogenesis in mouse mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1991;32:86
67. Tiwari RK, Suto A, Wong GY, Telang NT, Bradlow HL, **Osborne MP**.
Effect of indole-3-carbinol on human breast cancer cells.
Proceedings of the American Association for Cancer Research 1991;32:210
68. Tiwari RK, Mukhopadhyay B, **Osborne MP**.
Evaluation of desensitization of breast cancer cells to interferons using IFN-responsive genes.
Proceedings of the American Association for Cancer Research 1991;32:475
69. **Osborne MP**, Wong GY, Cote RJ, Liu J, Potter C, Killackey D, Old LJ, Rosen PP.
Breast cancer micrometastases in bone marrow: detection by fluorescein-labeled monoclonal antibodies predicts early relapse.
Proceedings of the American Society of Clinical Oncology 1991;10:45
70. Telang NT, Bradlow HL, **Osborne MP**.
Intermediate biomarkers for epithelial cell transformation: Relevance to cancer chemoprevention.
Journal of Cellular Biochemistry 1991;15:26
71. Massie MJ, Griffin AM, Rothman M, Fenner M, Jean LG, **Osborne MP**.
Prophylactic mastectomy: A reasonable treatment?
American Psychiatric Association, New Orleans, 1991
72. **Osborne MP**, Ruperto TF, Crowe JP, Rosen PP, Telang NT.
The effect of tamoxifen on preneoplastic cell proliferation in N-nitroso-n-methylurea-induced mammary carcinogenesis.
International Conference on Long-Term Antihormonal Therapy for Breast Cancer. Orlando 1991

73. Suto A, Bradlow HL, **Osborne MP**, Telang NT.
Effect of indole-3-carbinol on growth and estrogen metabolism of mouse mammary epithelial cells.
Breast Cancer Research and Treatment 1991;19:196
74. Tiwari RK, Suto A, Wong GY, Bradlow L, **Osborne MP**.
Cytotoxic effects of tumor necrosis factor in human breast cancer cells.
Breast Cancer Research and Treatment 1991;19:183
75. Telang N, Basu A, Bradlow HL, **Osborne MP**.
Intermediate biomarkers of transformation in mammary epithelial lines from the high cancer risk RIII mouse.
Breast Cancer Research and Treatment 1991;19:204
76. Wong GY, **Osborne MP**.
Breast cancer bone marrow micrometastases: a sensitive statistical analysis of the effect of systemic tumor cell burden.
Breast Cancer Research and Treatment 1991;19:171
77. Telang NT, **Osborne MP**, Bradlow HL.
Mammary explant culture: an ex-vivo model for chemopreventive efficacy of naturally occurring and synthetic antiestrogens.
Terra Symposium: Estrogens and Antiestrogens. Montauk, NY 1991
78. Dershaw D, McCormick B, **Osborne MP**.
Detection of local recurrence after conservative therapy for breast carcinoma.
Radiologic Society of North America, Chicago IL 1991
79. McKinnon WMP, Borgen PI, Hoffman B, Potter C, Wong GY, Kinne DW, **Osborne MP**.
Current management of male breast cancer: A review of 108 cases.
Southern Surgical Society, Homestead, VA 1991
80. Yahalom J, Petrek JA, Bidinger P, Kessler S, Dershaw D, **Osborne MP**, Kinne D, McCormick B, Rosen PP.
Breast cancer in patients irradiated for Hodgkin's Disease: A clinical and pathological analysis of 44 events in 37 women.
American Society of Therapeutic Radiation Oncology Washington, DC 1991
81. Telang NT, Bradlow HL, **Osborne MP**.
Molecular and endocrine biomarkers in non-involved breast: relevance to cancer chemoprevention Keystone Symposium on Cellular and Molecular Biology, Denver, CO 1991
82. Glicksman CA, Chaglassian TA, Kinne DW, Moore MP, Reichman BS, Potter CE, **Osborne MP**.
Immediate breast reconstruction with tissue expansion and concurrent systemic adjuvant chemotherapy.
American Society of Plastic and Reconstructive Surgery, Seattle WA, 1991

83. **Osborne MP**, Potter CE, Borgen PI, Wong GY, Lubin MB, Miller DG.
Surveillance programs for women at increased risk of breast cancer due to a family history in first degree relatives.
Proceedings of the American Society of Clinical Oncology 1992;11:147
84. Suto A, Bradlow HL, Wong GY, **Osborne MP**, Telang NT.
Prototypic chemopreventive agents downregulate preneoplastic transformation in carcinogen-treated mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1992;33:160
85. Garg A, Suto A, **Osborne MP**, Gupta RC, Telang NT.
DNA adducts and perturbed cellular functions in transformation-sensitive mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1992;33:169
86. Tiwari RK, Telang NT, Wong GY, Bradlow HL, **Osborne MP**.
Endocrine characteristics of normal human breast epithelial cells.
Proceedings of the American Association for Cancer Research 1992;33:274
87. Telang NT, Suto A, Wong GY, Bradlow HL, **Osborne MP**.
Genotoxic damage and aberrant proliferation by estrogen metabolites in mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1992;33:278
88. Lawlor KG, Telang NT, **Osborne MP**, Schaapveld RQ, Cho KR, Vogelstein B, Narayanan R.
Antisense RNA to the putative tumor suppresser gene "deleted in colorectal cancer" transforms fibroblasts.
Proceedings of the American Association for Cancer Research 1992;33:377
89. Banerjee D, Tiwari RK, **Osborne MP**, Bertino JR.
Transfection of MCF-7 breast cancer cells by v-Ha-ras results in increased resistance to methotrexate (MTX) and trimetrexate (TMTX).
Proceedings of the American Association for Cancer Research 1992;33:412
90. Tiwari RK, Pinto J, Qiao J, Dodds CH, Rivlin RS, **Osborne MP**.
Alteration in glutathione metabolism after transfection of V-H-ras oncogene in human breast carcinoma cells.
Proceedings of the American Association for Cancer Research 1992;33:495
91. Telang NT, Bradlow HL, Wong GY, **Osborne MP**.
Altered metabolism of estradiol in human mammary tissue: an endocrine biomarker for induction and modulation of preneoplastic transformation.
Proceedings of the American Association for Cancer Research 1992;
92. Telang NT, Bradlow HL, **Osborne MP**.
Intermediate biomarkers for mammary preneoplastic transformation: Relevance to cancer chemoprevention.
Anticancer Research 1992;12:1899-1900

93. Telang NT, Bradlow HL, **Osborne MP**.
Experimental down-regulation of biomarkers in mammary epithelial cell lines from "high" risk RIII mouse.
Breast Cancer Research and Treatment 1992;23:138
94. Tiwari RK, Pinto J, Qiao CH, Lin RIS, **Osborne MP**
Chemopreventive Effects of Garlic Compounds in Human Breast Carcinoma Cells.
Breast Cancer Research and Treatment 1992;23:171
95. Bradlow HL, Telang NT, Suto A, Leibel R, Wong GY, **Osborne MP**.
Paracrine effects of adipocytes on estrogen biotransformation in hormone responsive human mammary carcinoma cells.
Breast Cancer Research and Treatment 1992;23:173
96. **Osborne MP**, Cote RJ, Wong GY, Potter CE, Gonzalez A, Rosen PP.
Immunofluorescent monoclonal antibody (MAB) detection of breast cancer bone marrow micrometastases (BMM) in patients with unilateral invasive breast cancer: distribution by TNM stage.
Breast Cancer Research and Treatment 1992;23:136
97. Garin-Chesa P, Gonzalez A, Old LJ, **Osborne MP**, Rosen PP.
Detection of occult bone marrow micrometastases (BMM) in patients with epithelial cancer: technical aspects.
Modern Pathology 1992;5:119
98. **Osborne MP**, Potter CE, Borgen PI, Wong GY, Lubin MB, Miller DG.
Surveillance programs for women at increased risk of breast cancer due to family history in first degree relatives.
Proceedings of the American Association for Cancer Research 1992;11:147
99. Sepkovic DW, Murtezani S, Michnovicz J, **Osborne MP**, Bradlow HL.
Catechol estrogen production in female rat microsomes after treatment with Indole-3-Carbinol, ascorbigen or beta-naphthoflavone.
Proceedings of the American Association for Cancer Research 1993;34:77
100. Tiwari RK, Li G, Gonzalez A, Telang NT, **Osborne MP**.
Molecular effects of chemical carcinogens on non-transformed human breast epithelial cells.
Proceedings of the American Association for Cancer Research 1993;34:598
101. Suto A, Bradlow HL, Wong GY, Kubota T, Kitajima M, **Osborne MP**, Telang NT.
Antiproliferative and metabolic effects of selected tumor suppressive agents on MCF-7 human breast cancer cells.
Proceedings of the American Association for Cancer Research 1993;34:1457
102. Tiwari RK, Li G, Bradlow HL, **Osborne MP**.
Biochemical targets for the chemopreventive action of indole-3-carbinol in human breast cancer cells
Proceedings of the American Association for Cancer Research 1993;34:3278

103. Telang NT, Bradlow HL, **Osborne MP**.
In Vitro induction and modulation of preneoplastic transformation: A model for carcinogenesis and prevention.
Proceedings of the American Association for Cancer Research 1993;34:3279
104. **Osborne MP**, Wong GY, Gonzalez A, Potter C, Vlamis V, Cote RJ.
Bone marrow micrometastases (BMM) in breast cancer: The effect of systemic tumor cell (TC) burden on early relapse.
Proceedings of the American Society of Clinical Oncology 1993;12:102
105. Bergstein I, **Osborne MP**, Brown AMC.
Investigation of the possible role of wnt genes in human breast cancer.
Breast Cancer Research and Treatment 1993;27:161
106. Telang NT, Inoue S, Wong GY, Bradlow HL, **Osborne MP**.
Estrogen-mediated growth control of myc oncogene-transfected mammary epithelium: negative growth regulation by naturally-occurring antitumor compounds.
Breast Cancer Research and Treatment 1993;27:165
107. Tiwari RK, Guo L, Lin G, David D, **Osborne MP**, Bradlow HL.
Modulation of estradiol metabolism by pesticides in human breast carcinoma cells.
Proceedings of the American Association for Cancer Research 1994;35:1558
108. Halper M, Kash K, Breuer B, **Osborne MP**.
Recruitment strategy for the National Breast Cancer Prevention Trial of tamoxifen: response from a cohort with strong family histories of the disease.
Proceedings from the American Society of Preventive Oncology – 17th Annual Meeting 1993;
109. Tiwari RK, Guo L, **Osborne MP**, Fishman J.
Cellular and Molecular effects of metabolites of estradiol on T47D cells.
Proceedings of the American Association for Cancer Research 1994;35:1634
110. Telang NT, Inoue S, Bradlow HL, Fujiki H, **Osborne MP**.
Antipromotional effect of a green tea polyphenol on c-myc-transfected mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1994;35:3692
111. Singhal H, Cote RJ, Potter C, **Osborne MP**.
Bone marrow micrometastases (BMM) in breast cancer: relationship to local-regional disease status.
Proceedings of American Society of Clinical Oncology 1994;13:215
112. Bergstein I, Schultz R, Jenkins NA, Copeland NG, **Osborne MP**, Welcsh PL, Bowcock AM, Brown AMC.
Investigation of the possible role of wnt genes in human breast cancer.
Proceedings of the Fifth meeting on The Molecular Basis of Cancer 1994;26
113. Araki R, **Osborne MP**, Telang NT.
Inhibition of preneoplastic transformation in mammary epithelial cell line from the "high cancer risk RIII mouse".
Breast Cancer Research and Treatment 1994;32:216

114. Bradlow HL, Sepkovic DW, Kabat G, Ho G, Gong L, **Osborne MP**.
Application of estrogen metabolite ratios to risk assessment of hormone related cancers: preliminary results in breast and cervical cancer
Breast Cancer Research and Treatment 1994;32:244
115. Telang NT, Bradlow HL, **Osborne MP**.
Biomarkers of mammary preneoplastic transformation: end points for cancer chemoprevention
Proceedings of the XVI International Cancer Congress 1994;1285-1290
116. Telang NT, Acuri F, Granata OM, Bradlow HL, **Osborne MP**, Castagnetta L.
Altered metabolism of estradiol in myc oncogene transformed mammary epithelial cells: an endocrine biomarker for carcinogenesis.
The Endocrine Society 1994;879
117. Bergstein I, Schultz R, **Osborne MP**, Welch L, Bowcock AM, Brown AMC.
Investigation of the possible role of WNT genes in human breast cancer.
Annals of the New York Academy of Sciences 1995;768:257
118. Katdare MS, Singhal H, Newmark H, **Osborne MP**, Telang NT.
Aberrant hyperproliferation in mouse mammary epithelial cells: a biomarker for chemoprevention of preneoplastic transformation.
Proceedings of the American Association for Cancer Research 1995;35:738
119. Potter CE, Beldock JG, Rosenthal G, **Osborne MP**.
A clinician-friendly computer program for calculating breast cancer risk using the Gail and Claus Models.
Annals of the New York Academy of Sciences 1995;768:301
120. Bergstein I, **Osborne MP**, Brown MC.
Investigation of the possible role of WNT genes in human breast cancer
Proceedings of the American Association for Cancer Research 1995;35:3348
121. Tiwari RK, Li G, **Osborne MP**, Moroson H, Daou M, Srivastava PK.
Cancer derived purified heat shock protein, gp96, elicits protective immunity in a rat prostate cancer model.
Proceedings of the American Association for Cancer Research 1996;37:475
122. Katdare M, Sepkovic DW, Bradlow HL, **Osborne MP**, Telang NT.
Preventive efficacy of "Agent Purple" an herbal extract on NYC oncogene-transformed mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1996;37:268
123. Davis DL, Bradlow HL, Fishman J, **Osborne MP**, Telang NT.
Bifunctional hormonal/genetic pathways to breast cancer.
Proceedings of the American Association for Cancer Research 1996;37:241
124. Arzimanoglou LI, **Osborne MP**, Gilbert F.
Microsatellite instability in ovarian cancer.
Proceedings of the American Association for Cancer Research 1996;37:547

125. Telang NT, Katdare M, **Osborne MP**.
Negative growth regulation of HER-2/neu oncogene-transformed human mammary epithelial cells by a green tea polyphenol.
Breast Cancer Research & Treatment, 1996;41:318
126. Wong GYC, Katdare M, **Osborne MP**, Telang NT.
Prevention efficacy of Lentinus Edodes Mycelium extract (LEM) on human mammary carcinogenesis.
Breast Cancer Research & Treatment, 1996;41:321
127. Bradlow HL, Sepkovic D, Telang NT, **Osborne MP**.
Dietary modulation of estrogen metabolism: A novel approach to cancer chemoprevention.
Fundamentals of Cancer Prevention, 1996;41-44
128. **Osborne MP**.
Prognostic and therapeutic implications of bone marrow micrometastases.
Cancer Investigation, 1997;15:52.
129. Kash KM, Rosenthal G, Dabney MK, Miller DG, **Osborne MP**.
Comparisons of women at various risk levels for breast cancer on knowledge, interest and decision making about genetic testing.
American Society of Preventive Oncology, 1997
130. Kash KM, Holland JC, Rosenthal G, **Osborne MP**.
Decision making and willingness to undergo genetic testing for breast cancer in women at high risk.
American Psychosomatic Society, 1997
131. Kash KM, Holland JC, **Osborne MP**, Miller DG.
Genetic testing among women at risk for breast cancer knowledge, interest and decision making.
American Society of Preventive Oncology, 1997
132. Kash KM, Jacobsen PB, Holland JC, Miller DG, **Osborne MP**.
An instrument to measure breast cancer anxiety.
American Psychosomatic Society, 1997
133. Katdare M, **Osborne MP**, Telang NT.
Inhibition of aberrant proliferation and induction of apoptosis by the natural phytochemical genistein oncogene transformed human mammary epithelial cells.
Proceedings Indo-French Centre for Promotion of Advanced Research, 1997
Invitro Cellular & Developmental Biology 1997;33:V1004
134. Katdare M, Dannenberg A, **Osborne MP**, Telang NT.
Curcumin inhibits c-myc oncogene initiated tumorigenic transformation in mouse mammary epithelial cells.
Proceedings Indo-French Centre for Promotion of Advanced Research, 1997

135. Katdare M, **Osborne MP**, Telang NT.
Inhibitory effect of curcumin on chemically induced human mammary carcinogenesis: role of cell cycle modulation and apoptosis.
Proceedings Indo-French Centre for Promotion of Advanced Research, 1997
136. Telang NT, Katdare M, Bradlow HL, **Osborne MP**, Fishman J.
Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol.
Society for Experimental Biology and Medicine, 1997:246-252
137. Wong GW, Bradlow HL, Sepkovic D, Mehl S, Mailman J, **Osborne MP**.
A dose-ranging study of indole-3-carbinol for breast cancer prevention.
San Antonio Breast Cancer Symposium, 1997
138. Tiwari RK, Hoda S, Singhal H, Gonzalez A, Fishman JH, **Osborne MP**.
Cellular & molecular characterization of micrometastasis in breast cancer.
Department of Defense Breast Cancer Research Meeting, 1997; Vol. II, 703
139. Jinno H, Katdare M, **Osborne MP**, Telang NT.
Negative growth regulation of oncogene-transformed human mammary epithelial cells by phytochemicals: role of apoptosis.
Proceedings of the American Association for Cancer Research 1997;38:1400
140. Telang NT, Jinno H, Steiner MG, Nason-Burchenal K, **Osborne MP**.
Preventive efficacy of receptor class selective retinoids on HER/neu oncogene expressing preneoplastic human mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1998;39:2446
141. Jinno H, Steiner MG, Offord E, **Osborne MP**, Telang NT.
Inhibition of oncogene-induced aberrant proliferation by rosemary extract in human mammary epithelial cells.
Proceedings of the American Association for Cancer Research 1998;39:122
142. Wong GYC, **Osborne MP**.
Bone marrow micrometastatic tumor cell burden independently predicts breast cancer relapse.
Proceedings of the 21st Annual San Antonio Breast Cancer Symposium
Breast Cancer Research and Treatment 1998;50:280, abstract #319
143. Katdare M, **Osborne MP**, Telang NT.
Inhibitory effects of soy isoflavone genistein on preneoplastic human breast cells.
Proceedings of the 21st Annual San Antonio Breast Cancer Symposium
Breast Cancer Research and Treatment 1998;50:302, abstract #426
144. **Osborne MP**.
Chemoprevention of breast cancer.
Proceedings of the 1st Annual Roche International Symposium on Cancer Research,
1998;11:PS-1

145. Telang NT, Katdare M, Jinno H, **Osborne MP**.
Preclinical prevention of human breast carcinogenesis by natural phytochemicals: Role of cell regulation and apoptosis.
Proceedings of the American Association of Cancer Research 1999;40:3521
146. Telang NT, Katdare M, Kopelovich L, Kelloff GJ, **Osborne M**.
Growth inhibition of HER-2/neu oncogene expressing preinvasive human breast epithelial cells by N-(4-Hydroxyphenyl) retinamide and tamoxifen.
Proceedings of the American Association of Cancer Research 2000;41:55
147. Osborne, MP.
Micrometastatic cancer in bone marrow: A predictor of prognosis.
Monduzzi Editore 2001
148. Simmons R, Christos P, King V, **Osborne M**.
Analysis of nipple/areolar involvement with mastectomy
New York Surgical Society 2001
149. **Osborne MP**, Wong G
Breast cancer bone marrow micrometastases: a long term prognostic study
Proceedings of the American Society of Clinical Oncology 2002;21:58a
150. **Osborne MP**
Micrometastases in bone marrow
European Journal of Cancer 2004;2S:67-68
151. Gold HT, Do HT, **Osborne MP**
Cost-effectiveness of isosulphan blue vs. methylene blue in sentinel node biopsy.
Proceedings of the American Society of Clinical Oncology 2005; 23: # 16s 553s 6103
152. Crawford CV, **Osborne MP**, Katdare M
Identification of cell cycle and apoptosis related gene expression by curcumin in an *in vitro* model for duct carcinoma in-situ.
Proceedings of the American Association of Cancer Research 2005;46:1011 Abstract #4279
153. Tsai A, Trichter S, Sabbas A, Swistel A, **Osborne MP**, Hoda S, Nori D, Hayes MK
Short-term outcome of mammosite brachytherapy: A single institution's clinical experience.
American Society of Therapeutic Radiation Oncology 2006
154. Effectiveness of non-invasive digital infrared thermal imaging system in the detection of breast cancer.
Arora N, Swistel A, Tousimis E, **Osborne MP**, Simmons RS
American Society of Breast Surgeons 2008
155. Does Oncotype DX recurrence score affect management of patients with early breast cancer?
Asad J, Jacobson AF, Boolbol SK, Estabrook A, Feldman SM, **Osborne MP**,
Rosenbaum Smith S, Twarizk W, Tartter PI
American Society of Breast Surgeons 2008

156. Do additional shaved margins at the time of lumpectomy eliminate the need for reexcision?
Jacobson AF, Asad J, Boolbol SK, Osborne MP, **Osborne MP**, Boachie-Adjei K,
Feldman SM
American Society of Breast Surgeons 2008
157. How accurately can clinicians predict the Oncotype DX recurrence score?
Jacobson AF, Feldman SM, Fomberstein KM, **Osborne MP**, Malamud M, Shapira I,
Birham A, Boolbol SK
American Society of Breast Surgeons 2008

Lectures and Presentations

- 4/3/91 National Consortium of Breast Centers – Knoxville, TN
Keynote Speaker
The identification, management and strategies for prevention of women at increased risk for breast cancer: the role of the breast center.
- 3/12/92 NewYork Hospital – Cornell Medical Center – New York, NY
Public Service Seminar
What every woman should know about breast cancer.
- 4/29/92 National Council of Women of the United States, Inc. – New York, NY
Prevention and early detection of breast cancer.
- 5/14-15/92 European School of Oncology – Memorial Sloan-Kettering Cancer Center –New York, NY
Postgraduate Course: Conservative Treatment in Breast Cancer
Management of local recurrence.
- 6/24-26/92 Cancer Micrometastases: Biology, Methodology, and Clinical Significance – NCI, Bethesda, MD
Early clinical experience with breast cancer.
General methodological aspects: sensitivity.
- 9/09/92 North Shore University Hospital – Manhasset, NY
Grand Rounds Lecture
Breast cancer micrometastases in bone marrow: a predictor of early relapse.
- 10/8-9/92 Inštitút pre ďalšie vzdelávanie pracovníkov v zdravotníctve v Bratislave
Bratislava, Slovakia
Overview of risk factors for breast cancer and screening.
Current techniques of breast conservation, management of local recurrence and prevention of metastasis.
- 11/30/92 New York Roentgen Society – New York, NY
Surgical management of carcinoma in-situ.
- 12/8-10/92 15th Annual San Antonio Breast Cancer Symposium – San Antonio, TX
Immunofluorescent monoclonal antibody detection of breast cancer, bone marrow micrometastases in patients with unilateral invasive breast cancer: distribution by TNM Stage.
- 2/7-15/93 Kurume University and Keio University Hospital, Japan - Zen-Yaku Pharmaceutical Co. Ltd.,
The estrogen metabolite 16-alpha- hydroxyestrone: an initiator/promoter of breast cancer?
Bone marrow micrometastasis detected by monoclonal antibodies predict the early relapse of breast cancer.

- 2/15–18/93 Kwong Wah Hospital - Department of Surgery - Hong Kong
New approaches to breast cancer induction and detection of occult metastasis.
- 2/27/93 New York Metropolitan Breast Cancer Group, 20th Annual Breast Cancer Symposium - New York, NY
The NSABP Trials.
- 4/30/93 American College of Surgeons – Hershey, PA
A comparison of the results with different modalities of treatment in Stage I & II breast cancer.
Management of nipple discharge.
Management of recurrent local disease after breast preserving procedures.
- 5/6/93 New York Roentgen Society – New York, NY
Surgical management of advanced breast cancer.
- 5/6-7/93 European School of Oncology – Memorial Sloan-Kettering Cancer Center, New York, NY
Postgraduate course: Controversies in Breast Cancer
The biological basis of local-regional treatment options.
- 9/29/93 American Cancer Society – Rockefeller University, New York, NY - Cancer Prevention and Early Detection: Practice Perspectives, Controversies and Future Directions
Controversies in breast cancer prevention.
- 10/2-5/93 New York Clinical Society-New York, NY
Breast cancer: The history of surgical oncology.
- 10/4-8/93 European School of Oncology – Orta San Giulio, Italy
Breast Cancer Co-Chairperson.
The importance of local regional treatment in the natural history of breast cancer.
Round table: Premalignant lesions, in-situ breast carcinoma: Biological behavior and management.
Risk factors and management of breast recurrences after conservative treatment.
- 10/10-15/93 American College of Surgeons Annual Meeting – San Francisco, CA
Proliferative breast disease and cancer risk.
- 10/31-11/8/93 Argentine Society of Mastology Postgraduate Course: Buenos Aires, Argentina
Keynote Lecture
Chemoprevention in breast cancer.
Identification and management of women at risk for breast cancer.
Epidemiology in breast pathology.
An overview of the biological basis of breast cancer treatment.
Current indications of mastectomy.
- 11/18-19/93 British Association of Cancer Research/British Association of Surgical Oncology Science Forum – London, UK
Modulators of mammary epithelial growth and transformation.

- 11/30/93 3rd Annual Solid Tumor Symposium – New York Medical College/Westchester County Medical Center, Valhalla, NY
Bone marrow micrometastases: A predictor of breast cancer recurrence?
- 3/9/94 New York Hospital/Cornell Medical Center – Division of Plastic Surgery
New York, NY
Mastectomy and breast surgery.
- 3/9/94 New York Surgical Society – New York, NY
Discussant
Ultrasound-guided fine needle aspiration cytology – early experience with a new and logical approach.
- 4/5/94 Hackensack University Medical Center – Department of Surgery - Hackensack, NJ
Bone marrow micrometastases in breast cancer as a predictor of early relapse.
- 4/11/94 MedCom Systems, Inc. National Teleconference “Advances in Screening, Diagnosis, and Treatment of Breast Cancer” - Philadelphia, PA
Breast cancer surgical treatment.
- 5/8-12/94 8th International Congress on Senology (Breast Diseases) of The Senologic International Society (SIS) – Rio de Janeiro, Brazil
Primary Prevention in Breast Cancer: Diet and nutritional factors.
Breast Cancer Therapy: Discussant.
Epidemiology of Breast Cancer: Identification and management of women at increased risk.
Local Recurrences: Contralateral breast approach.
Controversies in Breast Cancer Treatment: Biological basis for breast cancer treatment options.
- 10/1/94 New York Hospital/Cornell Medical Center Frontiers in oncology-hematology New York, NY
Breast cancer.
- 10/3-5/94 European School of Oncology, Milan, Italy - Advanced Course: Breast Cancer
Co-Chairperson.
The importance of local regional treatment on the natural history of breast cancer.
Risk factors and management of breast recurrences.
- 10/12/94 80th Annual Clinical Congress American College of Surgeons, Chicago, IL Postgraduate Course: Breast Surgery
Breast conservation: predictors and management of local recurrence.
- 10/25/94 Lenox Hill Hospital – Department of Surgery Grand Rounds - New York, NY
Breast cancer risk: management and psychological issues.
- 11/16/94 Brown University Medical College/Rhode Island Hospital - Department of Surgery Grand Rounds – Providence, RI
Bone marrow micrometastases: a predictor of systemic disease.

- 12/15/94 3rd Annual Cyril S. Arvanitis Lectureship Program - Monmouth Surgical Society
Long Branch, NJ
Breast cancer: past, present and future.
- 1/29-2/3/95 20th Annual Post-Graduate Course: – New York Hospital/Cornell
University Medical College, Aruba - Diagnostic Imaging – Current Status
in Selected Topics with Treatment Commentaries
Breast conserving surgery and radiation therapy.
Identification and management of women at enhanced risk for breast cancer.
Biological basis of breast cancer treatment options.
- 2/24-25/95 17th Annual Oncology Update: New Diagnostic Treatments and
Techniques for Cancer and Treatment of Early Diagnosed Cancer –
Miami, FL
The identification and management of patient at increased risk for breast cancer.
Detection of bone marrow micrometastases: A new prognostic variable.
- 3/10-11/95 American Society of Breast Disease Annual Meeting, New York
Metropolitan Breast Cancer Group & Memorial Sloan-Kettering Cancer
Center
New York, NY
Dilemmas in surgery and radiation therapy.
- 4/1-6/95 E. Majorana Centre for Scientific Culture, International School of
Pharmacology, Erice, Sicily Propedeutics to Cancer Management –
Co-Chairman of Session
Hormonal interventions in breast cancer: Past, present and future.
- 5/20-23/95 American Society of Clinical Oncology Los Angeles, CA
Abstract Discussion Leader.
High dose therapy.
- 6/1/95 Maimonides Medical Center - Surgical Oncology Grand Rounds –
Brooklyn, NY
Bone marrow micrometastases.
- 9/26/95 North Shore University Hospital, Oncology Conference Manhasset, NY
Identification and management of women at risk for breast cancer in the era of
molecular genetics.
- 11/8/95 New York Hospital/Cornell Medical Center Division of Plastic Surgery Grand Rounds
New York, NY
Breast cancer.
- 2/23/96 Mount Sinai Medical Center Division of Neoplastic Diseases Grand
Rounds - New York, NY
Prognostic and therapeutic implication of occult bone marrow micrometastases.

- 4/16/96 American College of Surgeons Postgraduate Courses: Update on the Treatment of Cancer of the Colon and Breast - – New York, NY
Identification and management of women at risk for breast cancer in the era of molecular genetics.
- 6/28-29/96 Hokkaido University – Sapporo, Japan
Identification and management of women at risk for breast cancer in the era of molecular genetics.
- 10/6-11/96 Breast Disease - American College of Surgeons – San Francisco, CA
Postgraduate Course: Management of the abnormal screening mammogram.
- 10/31/96 Chemotherapy Foundation Symposium – Innovative Cancer Therapy for tomorrow – The Division of Neoplastic Diseases/Mount Sinai School of Medicine, New York, NY
Prognostic and therapeutic implications of bone marrow micrometastases.
- 12/13/96 1st Network New York Hospital/Cornell Medical Center Seminar:
Advances in Oncology – New York, NY
Breast cancer treatment outcome analysis.
- 2/12/97 United Hospital - Mamaroneck, NY
Recent progress in breast cancer risk evaluation, prevention, early diagnosis and treatment.
- 1/26-31/97 25th Anniversary Diagnostic Radiology Postgraduate Course: The New Wave in Diagnosis and Treatment – Department of Radiology, Cornell University Medical College & the New York Hospital, Puerto Rico
Special Lecture: Halsted: Personal tragedy to professional triumph
Breast cancer biology: Indications for treatment
Identification and management of women at risk for breast cancer in the molecular era
Precursor lesions for breast carcinoma: Diagnosis and treatment.
- 2/25/97 New York Methodist Hospital Surgical Grand Rounds - Brooklyn, NY
Bone marrow in breast cancer prognostic and therapeutic implications.
- 3/6-8/97 14th Annual Miami Breast Cancer Conference – Miami, FL
Halsted: Personal tragedy to professional triumph.
- 10/31-11/4/97 US Army Medical Research and Material Command's 1997 Meeting:
DOD Breast Cancer Research Program: "An Era of Hope" Department of Defense, Washington, DC
Identification of primary tumor markers in occult bone marrow micrometastases.
- 12/12/97 2nd Annual Seminar on Advances in Oncology Breast Cancer Management Today and Tomorrow – New York Hospital/Cornell Medical Center, New York, NY
New perspectives in the management of breast cancer.
- 6/19/98 Surgery Update 1998 – New York Hospital/Cornell Medical Center, New York, NY
Halsted in New York: An historic view.

- 6/10-12/98 Schweitzer Seminar on Cancer – Prague, Czech Republic
Epidemiology, prevention and early detection of breast cancer.
- 9/10/98 Emerging Strategies for Cancer Therapy in the New Millennium – New York Methodist Hospital, Brooklyn, NY
Selective axillary lymph node dissection: The role of sentinel node biopsy.
- 10/7/98 The Latest News about Breast Cancer Prevention, Diagnosis and Treatment – New York Hospital/Cornell Medical Center & Strang Cancer Prevention Center, New York, NY
Prevention strategies.
- 10/25-30/98 American College of Surgeons Annual Meeting, Orlando, FL
Breast Disease Postgraduate Course:
Who doesn't need adjuvant chemotherapy: The role of novel prognostic markers?
- 11/21-22/98 1st Roche International Symposium on Cancer Research – Kyoto, Japan
Chemoprevention of breast cancer.
- 12/9-11/98 15th Annual Controversies, Problems and Techniques in Surgery – Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY
Controversy: Axillary dissection in early stage breast cancer: To do or not to do?: Selective management of the regional nodes
Problems in breast surgery: Identification of increased risk of breast cancer and strategies for prevention. Panel Discussant.
- 5/12/99 Public Education Meeting SHARE Program/Lord & Taylor, New York NY
New frontiers: Nutritional and pharmacological means to reduce risk of breast cancer.
- 6/16-18/99 63rd Annual Course in Advances in Breast, Endocrine and Cancer Surgery
University of Minnesota, Minneapolis, MN
Risk factors in breast cancer and the role of genetics.
Are biological markers of significant practical value in breast cancer?
Panelist.
- 3/2-4/00 17th Annual Miami Breast Cancer Conference – Miami, FL
Moderator of special session on sentinel nodes
Overview of breast cancer prevention.
Value of prognostic markers including the role of bone marrow micrometastases.
Pitfalls in the management of breast cancer: A medical/legal perspective.
Umberto Veronesi: A man for all seasons.
- 4/14-15/00 Annual Meeting American Society of Breast Surgeons – Charleston, SC
Chemoprevention in the management of high-risk patients
Medical-legal aspects of breast cancer treatment.
Micrometastatic cancer in bone marrow – a predictor of prognosis.

- 5/2/00 Hackensack University Medical Center Surgical Grand Rounds Hackensack, NJ
Preventing breast cancer.
- 5/14-18/00 IX International Congress of Senology, – Cancun, Mexico
Keynote Lecture – Women at High Risk for Breast Cancer: Identification and Management
Axillary dissection
Cancer prevention.
Bone marrow micrometastases: A prognostic factor for breast cancer?
- 6/10/00 Breast Imaging Seminar New York Roentgen Society, New York, NY
Breast cancer treatment today: Surgery, radiation and chemotherapy.
- 6/14-16/00 2nd Milan Breast Cancer Conference - Milan, Italy The role of the internet.
Satellite Symposium on Breast Cancer and the Media: A Challenge for Doctors and Nurses
- 10/19/00 Irish Traveling Surgeons – NewYork-Presbyterian Hospital/NY Weill Cornell Center/Weill Medical College of Cornell University, New York, NY
Chemoprevention of breast cancer.
- 10/21/00 Cornell Medical Center Alumni Symposium: Women's Health in the New Millennium – Weill Medical College of Cornell University, New York, NY
(Substitute speaker for Antonio Novella, MD. New York State Health Commissioner)
Opening remarks.
- 10/23/00 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology Boston, MA
Breast cancer case management panel in early stage invasive breast cancer (AJCC Stages III) and duct carcinoma in-situ (Stage 0).
- 2/15/01 Cancer & Fertility: The Latest Options – Resolve NYC, New York, NY
Panelist.
- 3/16/01 Royal College of Surgeons of England – NewYork Weill Cornell Center, New York, NY
The surgeon in the breast cancer patient's journey.
- 3/21/01 Department of Radiation Oncology Grand Rounds New York Methodist Hospital Brooklyn, NY
Identification and management of women at increased risk of breast cancer.
- 3/24-28/01 American Association for Cancer Research, New Orleans, LA - Progress and New Hope in the Fight against Cancer: A Public Forum Highlighting the Latest Discoveries: Ask the Experts –
Breast cancer: Early detection of metastases.

- 4/27/01 Cancer Genetics & Genomics – Weill Medical College, New York, NY
Hereditary breast cancer.
The individual at risk: A case study.
Gene testing and the surrounding issues.
Using the knowledge: Follow-up and patient care.
- 4/27-29/01 25th Annual Meeting of the American Society of Breast Disease
New York, NY
Micrometastases' prognostic and therapeutic implications.
Moderator.
- 4/30/01 New York Clinical Society New York, NY
The Hunters: Brother Surgeons.
- 5/17/01 New York Hospital/Cornell Medical Center Department of Surgery Grand Rounds –
New York, NY
Bone marrow micrometastases.
- 6/13-15/01 3rd Milan Breast Cancer Conference – Milan, Italy
Bone marrow micrometastases.
- 10/14/01 7th Annual Breast Cancer Awareness Day SASS Foundation,
Huntington, NY
Eileen Dryer Memorial Lecture – Keynote Speaker.
Advancements in the management of breast cancer.
- 12/5-7/01 18th Annual Controversies, Problems and Techniques in Surgery – Albert
Einstein College of Medicine/Montefiore Medical Center, New York, NY
Bone marrow micrometastases: Diagnosis at surgery.
Role of tamoxifen as adjuvant therapy and chemoprevention.
Panelist.
- 2/14-16/02 International Society for Cancer Chemoprevention, Tumor Prevention and Genetics
2002
St Gallen, Switzerland
Secondary prevention of breast cancer: The mammography controversy.
Moderator.
- 3/3-5/02 Lung Screening Seminar, Paris, France
Speaker and Workshop Chair.
Principal measure of breast cancer screening's usefulness.
- 4/26/02 Weill Medical College, Cancer Genetics and Cancer Genomics
New York, NY
Hereditary breast cancer.
Case study: The individual at risk and family issues.
Gene testing and the surrounding issues.
Sporadic breast cancer.
Management of node negative breast cancer.

- 4/28/02 American Society of Breast Surgeons, 3rd Annual Scientific Meeting,
Boston, MA
Clinical significance of circulating tumor cells
Bone marrow micrometastases.
- 5/18-21/02 American Society of Clinical Oncology – Orlando, FL
Poster Session.
Breast cancer bone marrow micrometastases: A long-term prognostic study of
systemic tumor cell burden in relapse.
- 5/30/02 New York Hospital/Cornell Medical Center, Department of Surgery
Grand Rounds, New York, NY
Anatomy of a surgical malpractice trial.
- 10/6-10/02 American College of Surgeons Clinical Congress Postgraduate Course #30 – A
Surgeon's Personal Guide to Risk management and Trial Participation - - San
Francisco, CA
Mock trial: Summary of the facts. Defendant.
- 10/14-18/02 Frontiers in Cancer Prevention Research: Genetics, Risk Modeling, Molecular Targets
for Chemoprevention, Behavioral Prevention Research, Clinical Prevention Trials,
Science and Public Policy – American Association for Cancer Research Boston, MA
Chairperson
Symposium: The role of prophylactic surgery in cancer prevention.
- 10/17/02 The National Council on Women's Health Making Decisions About Hormone Level
Replacement Therapy? Ask the Experts – UN Plaza, New York, NY
Panelist.
- 11/11/02 Breast Cancer Orientation Course in Cooperation with the Brazilian Society of
Mastology – Memorial Sloan-Kettering Cancer Center, New York, NY
Prognostic significance of bone marrow micrometastases.
Discussion and case presentation on a case of sentinel lymph node metastases.
- 3/5 – 3/9/03 Society of Surgical Oncology Cancer Symposium – Meet the Professor
Los Angeles, CA
Early stage breast cancer: Are nodal and bone marrow micrometastases important?
- 3/25/03 New York Medical College, Department of Surgery Grand Rounds, Valhalla, NY
New developments in breast cancer research and management.
- 4/29/03 New York Methodist Hospital, Department of Surgery Grand Rounds
Brooklyn, NY
Breast cancer: Current update and future trends
- 6/11-6/13/03 67th Annual Course in Advances in Breast, Endocrine and Cancer Surgery,
University of Minnesota, Minneapolis, MN
Care of Women with BRCA I or BRCA II mutations
Antiestrogen trials in prevention of breast cancer

- 10/23/03 Breast Cancer and the Environment at the Carriage House
New York, NY
The prevention of breast cancer: History, screening and nutrition
- 12/3-12/6/03 San Antonio Breast Cancer Symposium, San Antonio, TX
Bone marrow micrometastasis is a significant predictor of long-term relapse-free survival for breast cancer by a non-proportional hazards model.
- 3/16-3/20/04 4th European Breast Cancer Conference, Hamburg, Germany
Micrometastases in bone marrow
- 5/12-5/16/04 Catholic University of Rome Department of Surgical Sciences in cooperation with
Komen Foundation, Rome, Italy
Guidelines for the management of women at increased risk of breast cancer
- 11/14/04 School of Breast Oncology, Keynote address. Historical perspective of breast cancer.
Atlanta, GA
- 11/19-20/04 The 4th International Symposium on Cancer Research and Therapy.
Tokyo, Japan
Cancer chemoprevention for breast cancer
- 5/10/05 Hackensack University Medical Center Department of Surgery Grand Rounds
Hackensack, NJ
Breast cancer update
- 10/24/05 New York Clinical Society
New York, NY
Breast cancer: Hieroglyphics to Herceptin
- 02/16-18/06 4th International Conference – Cancer Prevention 2006
University of St. Gallen, Switzerland
Advances in Molecular and Clinical Aspects of Cancer Prevention.
Discussant
- 04/05/06 The Philadelphia Academy of Surgery Conjoint Meeting with the New York Surgical
Society
Philadelphia, Pennsylvania
Correlation of positive peripheral blood and bone marrow aspirates with genomic
assay for high risk of recurrence in breast cancer
Discussant
- 05/11/06 Weill Cornell Breast Center's Eighth Annual Symposium on the Latest News About
Breast Cancer
New York, NY
Breast surgery: Less is more

- 05/24/06 St. Luke's-Roosevelt Hospital Department of Surgery Grand Rounds
New York, NY
William Stewart Halsted, MD
- 09/06-10/06 The Halsted Society 80th Annual Meeting
Charleston, SC
Halsted's contribution to charting vital signs at the New York Hospital
- 01/25/07 Long Island Jewish Medical Center Department of Surgery Grand Rounds
New York, NY
Breast cancer: Less is more
- 02/07/07 New York Surgical Society
New York, NY
Sentinel node positivity rates with and without frozen section for breast cancer
- 03/20/07 New York Methodist Hospital, Department of Surgery Grand Rounds
Brooklyn, NY
Breast cancer: Targeted treatment
- 04/12-14/07 Thirty-Sixth Annual Post Graduate Course in Surgery – Department of Surgery
Medical University of South Carolina
Charleston, SC
Current concepts in breast cancer: Less is more
Closing the barn door after horse has bolted: Mastectomy in patients with stage IV cancer
- 12/06/07 Twenty Fourth Annual Controversies, Problems and Techniques in Surgery
Albert Einstein College of Medicine / Montefiore Medical Center New York NY
What to do when ADH, ALH, LCIS and papillary lesions are found on core biopsies?
What is an adequate margin and how is it achieved?
- 3/25/08 Grand Rounds Department of Medicine, Beth Israel Medical Center, New York
Breast Cancer Treatment: Less is more
- 6/20/08 Grand Rounds Department of Radiation Oncology, Continuum Cancer Centers of New York
Breast Cancer: Hieroglyphics to Herceptin
- 10/28/08 Grand Rounds Department of Surgery, New York Methodist Hospital, New York
Breast Cancer: Hieroglyphics to Herceptin
- 12/11/09 Twenty Sixth Annual Controversies, Problems and Techniques in Surgery
Albert Einstein College of Medicine / Montefiore Medical Center New York NY

Management of Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, Papillary Lesions and LCIS on Stereotactic Biopsy: Management Options

Prophylactic Mastectomy: Indications and Outcomes

- 4/22/10 The Venet Lecture. Beth Israel Medical Center, New York NY
Five Thousand Years of Breast Cancer Treatment
- 5/18/10 Management of Breast Diseases 2010, Course director, Continuum Cancer Centers of
New York, New York
- 6/14/13 Cancer Follow-up for Primary Care Physicians, Course Director, Beth Israel Medical
Center, New York